<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacy (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacy (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmacy</journal-id><journal-title-group><journal-title>Pharmacy</journal-title></journal-title-group><issn pub-type="epub">2226-4787</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998019</article-id><article-id pub-id-type="pmc">PMC11859822</article-id>
<article-id pub-id-type="doi">10.3390/pharmacy13010021</article-id><article-id pub-id-type="publisher-id">pharmacy-13-00021</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Medication Non-Adherence in Inflammatory Bowel Disease: A Systematic Review Identifying Risk Factors and Opportunities for Intervention</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6724-2288</contrib-id><name><surname>King</surname><given-names>Kathryn</given-names></name><xref rid="af1-pharmacy-13-00021" ref-type="aff">1</xref><xref rid="c1-pharmacy-13-00021" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9889-1248</contrib-id><name><surname>Czuber-Dochan</surname><given-names>Wladyslawa</given-names></name><xref rid="af1-pharmacy-13-00021" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0775-1045</contrib-id><name><surname>Chalder</surname><given-names>Trudie</given-names></name><xref rid="af2-pharmacy-13-00021" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Norton</surname><given-names>Christine</given-names></name><xref rid="af1-pharmacy-13-00021" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Schommer</surname><given-names>Jon</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmacy-13-00021"><label>1</label>Florence Nightingale Faculty of Nursing Midwifery and Palliative Care, King&#x02019;s College London, London SE1 8WA, UK; <email>wladzia.czuber-dochan@kcl.ac.uk</email> (W.C.-D.); <email>christine.norton@kcl.ac.uk</email> (C.N.)</aff><aff id="af2-pharmacy-13-00021"><label>2</label>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King&#x02019;s College London, London SE5 8AB, UK; <email>trudie.chalder@kcl.ac.uk</email></aff><author-notes><corresp id="c1-pharmacy-13-00021"><label>*</label>Correspondence: <email>kathryn.king@kcl.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>1</issue><elocation-id>21</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>18</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Inflammatory bowel disease (IBD) is treated with medications to induce and maintain remission. However, many people with IBD do not take their prescribed treatment. Identifying factors associated with IBD medication adherence is crucial for supporting effective disease management and maintaining remission. Quantitative and qualitative studies researching IBD medication adherence between 2011 and 2023 were reviewed. In total, 36,589 participants were included in 79 studies. The associated non-adherence factors were contradictory across studies, with rates notably higher (72&#x02013;79%) when measured via medication refill. Non-adherence was lower in high-quality studies using self-report measures (10.7&#x02013;28.7%). The frequent modifiable non-adherence risks were a poor understanding of treatment or disease, medication accessibility and an individual&#x02019;s organisation and planning. Clinical variables relating to non-adherence were the treatment type, drug regime and disease activity. Depression, negative treatment beliefs/mood and anxiety increased the non-adherence likelihood. The non-modifiable factors of limited finance, younger age and female sex were also risks. Side effects were the main reason cited for IBD non-adherence in interviews. A large, contradictory set of literature exists regarding the factors underpinning IBD non-adherence, influenced by the adherence measures used. Simpler medication regimes and improved accessibility would help to improve adherence. IBD education could enhance patient knowledge and beliefs. Reminders and cues might minimise forgetting medication. Modifying risks through an adherence support intervention could improve outcomes.</p></abstract><kwd-group><kwd>inflammatory bowel disease</kwd><kwd>medication non-adherence</kwd><kwd>medication non-concordance</kwd><kwd>medication non-compliance</kwd><kwd>medication non-persistence</kwd><kwd>systematic review</kwd></kwd-group><funding-group><award-group><funding-source>National Institute for Health and Care Research (NIHR) Doctoral Fellowship Program</funding-source><award-id>NIHR302646</award-id></award-group><funding-statement>This research was funded by the National Institute for Health and Care Research (NIHR) Doctoral Fellowship Program [NIHR302646 to K.E.K.]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Funding sources were not involved in the study design, collection, analysis, data interpretation or the writing of the report, and the supporting source had no such involvement or restrictions regarding publication.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmacy-13-00021"><title>1. Introduction</title><p>Inflammatory bowel disease (IBD) refers to the chronic inflammatory diseases of Crohn&#x02019;s disease (CD) and ulcerative colitis (UC). Worldwide, there were 4.90 million IBD cases in 2019 [<xref rid="B1-pharmacy-13-00021" ref-type="bibr">1</xref>], an almost 50% increase since the 1990s. Historically, IBD has been most prevalent in developed regions; however, recently there has been a rapid rise in incidence within the Middle East, Asia, and South America.</p><p>These incurable conditions are associated with an excessive immune response leading to unpredictable disease course, impacting quality of life and causing long-term consequences such as gut damage and colorectal cancer [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>]. The most frequently reported symptoms in remission are fatigue, chronic pain, incontinence and extra-intestinal manifestations such as arthritis. Diagnostic examinations are typically reported as &#x0201c;painful&#x0201d; and &#x0201c;stressful&#x0201d; by patients [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>]. Medication therapy aims for &#x0201c;tight control&#x0201d; of inflammatory activity and to induce and maintain symptomatic, endoscopic and histological remission whilst reducing the risk of sequalae [<xref rid="B4-pharmacy-13-00021" ref-type="bibr">4</xref>]. Some medications also decrease the incidence of colorectal cancer, e.g., mesalazine. However, the protective effect requires strict adherence. High non-adherence prevalence (up to 72%) has been reported across a range of IBD drugs and healthcare systems [<xref rid="B5-pharmacy-13-00021" ref-type="bibr">5</xref>]. Non-adherence to IBD medications can significantly impact treatment outcomes, with studies associating it with increased risks of disease flare [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>] and a reduced quality of life [<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>]. Non-adherence in IBD leads to high healthcare and societal costs [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-13-00021" ref-type="bibr">10</xref>].</p><p>Researching and understanding adherence is complex. Defining, measuring and identifying patients with a high possibility of non-adherence, as well as understanding and supporting medication adherence, is a challenge [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>]. A combination of determinants have been found to influence non-adherence, including patient-related and healthcare-related factors [<xref rid="B12-pharmacy-13-00021" ref-type="bibr">12</xref>]. Yet typically, studies have investigated only a one or two of these individually.</p><p>This is mirrored throughout healthcare, across multiple health conditions. Several theories have been proposed as to why people are non-adherent to their medication, with recognition that some factors can be modifiable and can be addressed. This includes health psychology and cognitive behavioural theories [<xref rid="B13-pharmacy-13-00021" ref-type="bibr">13</xref>] (health belief model, social cognitive theory, and theory of planned behaviour) which consider an individual&#x02019;s cognition as a key behaviour change factor. Alternatively, biopsychosocial models attribute various physical and psychosocial influencers to explain non-adherence [<xref rid="B14-pharmacy-13-00021" ref-type="bibr">14</xref>].</p><p>Knowing why a person with IBD is non-adherent would enable the development of tailored and effective interventions to improve self-management and adherence in this chronic condition, whilst reducing costs. Previous work has considered either adherence, non-adherence or related concepts in IBD individually or focussed upon specific medication types [<xref rid="B12-pharmacy-13-00021" ref-type="bibr">12</xref>,<xref rid="B15-pharmacy-13-00021" ref-type="bibr">15</xref>]. Earlier scoping and systematic reviews identified the complexity of related factors on non-adherence across a range of conditions [<xref rid="B16-pharmacy-13-00021" ref-type="bibr">16</xref>,<xref rid="B17-pharmacy-13-00021" ref-type="bibr">17</xref>], yet a comprehensive systematic review focussed upon IBD is lacking. This piece will build upon previous reviews of all IBD medication non-adherence terms over an extended time period. The aim of this review is to systematically explore and synthesise the available evidence of both modifiable and non-modifiable factors associated with non-adherence in people with IBD. This will help to identify both modifiable targets for health interventions to enhance and maintain adherence and non-modifiable targets which should be clinically monitored and supported wherever possible to minimise non-adherence.</p></sec><sec id="sec2-pharmacy-13-00021"><title>2. Materials and Methods</title><p>
<bold>Search strategy</bold>
</p><p>Six electronic databases were searched systematically in November 2023. Published articles from peer-reviewed journals relevant to the review&#x02019;s aims were identified. The reference lists of the included studies were searched for appropriate papers. A combination of terms relating to adherence and IBD was used to search the databases. A full list of search terms, adapted for each database, is presented in <xref rid="app1-pharmacy-13-00021" ref-type="app">Supplementary Table S1a,b</xref>. Retrieved studies were exported into EndNote (Version 20) and transferred to the Covidence (Version 2) reference management software. Bias was minimised through two reviewers (K.K. and C.N.) screening 50% each of the titles and abstracts of retrieved papers for eligibility, according to pre-determined inclusion criteria. Reviewers were assigned full-text papers for data extraction, with K.K. performing double data extraction. Any disagreements were resolved through discussion with a third reviewer (W.C.D.). A flow diagram (<xref rid="app1-pharmacy-13-00021" ref-type="app">Supplementary Figure S1</xref>) reports the study selection process and provides reasons for inclusion and exclusion as suggested by the PRISMA-P guidelines [<xref rid="B18-pharmacy-13-00021" ref-type="bibr">18</xref>]. The protocol was registered in PROSPERO [CRD42021240056].</p><p>
<bold>Inclusion Criteria</bold>
</p><p>All papers in English, published from 2011 to November 2023, where the majority of participants were &#x02265;16 years old, with a diagnosis of IBD and prescribed one or more medication for IBD, were included. A cut-off of 12 years was considered extensive for the previous literature, whilst considering contemporary, relevant IBD medications. Papers were excluded if the study population were all children/young people (&#x0003c;16 years old), not living with IBD or not prescribed medication for IBD. Bias was minimised through conducting a thorough review of available published literature. Peer-reviewed papers of qualitative or quantitative study design were included investigating factors associated with adherence and non-adherence in adults living with IBD. Grey literature was not considered due to the volume of papers identified within the specified period. Intervention studies, reviews/protocols or conference abstracts were excluded from this review, as were papers not written in English.</p><p>As the review&#x02019;s aim was to investigate factors associated with any type of non-adherence, where papers reported adherence, outcomes were reversed to non-adherence to ensure meaningful comparisons. When studies used alternative terms to describe not taking medication as prescribed (compliance/non-compliance, concordance/non-concordance and persistence/non-persistence), these were also included. When studies differentiated between persistence/non-persistence or discontinuation and non-adherence, the study was only included if non-adherence/adherence was reported separately as a primary outcome (See <xref rid="app1-pharmacy-13-00021" ref-type="app">Supplementary Figure S1</xref>).</p><p>
<bold>Analyses</bold>
</p><p>Most studies included were quantitative and did not control for potential confounders, presenting only univariate (one variable) or bivariate (two variables) data analysis. Due to the need to control for other factors within a model, the increased likelihood of larger samples being used in multivariable analysis (MVA) and the large number of studies found overall, only factors significant in MVA were considered most likely related to non-adherence. If methods were stated as multiple linear regression, multiple logistic regression, multivariate analysis of variance (MANOVA), factor analysis, cluster analysis or multivariable analysis, we included this as MVA. If data were stated as being statistically significant at univariate or bivariate analysis, but non-significant at MVA, this was also reported.</p><p>
<bold>Quality Appraisal</bold>
</p><p>The Critical Appraisal Skills Programme (CASP) tools were used to assess the quality of both qualitative and quantitative papers. Qualitative studies were appraised using the CASP checklist for qualitative data [<xref rid="B19-pharmacy-13-00021" ref-type="bibr">19</xref>]. For quantitative papers, in line with the CASP tool recommendations [<xref rid="B20-pharmacy-13-00021" ref-type="bibr">20</xref>], a CASP scoring system was not used and a systematic rating system was devised for quality rating by the research team. Each quantitative study was given a total base score of &#x0201c;three&#x0201d;; one point was subtracted if the study did not use a reliable, recognised adherence measure and one point was subtracted if authors did not specify the use of a form of MVA. This resulted in scores of three (high), two (medium) or one (low). If study reporting was unclear and/or with limited data, the study was reviewed again by reviewers and scores amended. No studies were excluded based on quality.</p></sec><sec sec-type="results" id="sec3-pharmacy-13-00021"><title>3. Results</title><p>A total of 7596 papers were identified from six databases and the reference lists of the included studies. After screening titles and abstracts, 384 papers remained with full-text eligibility screening. A total of 79 papers were identified for the review, undergoing data extraction. Studies were conducted between 2011 and 2023, across the world, including Europe (32 studies), North America (20 studies), South America (4 studies) Asia (18 studies), and Oceania (3 studies). Two studies conducted their research multi-nationally [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B21-pharmacy-13-00021" ref-type="bibr">21</xref>]. While many included single sites (38 studies) based within general or tertiary hospitals settings, some were multi-site (32 studies) or not site-specific (9 studies, e.g., online).</p><p>
<bold>Demographics of participants</bold>
</p><p>In total, 36,589 participants were included, ranging from 7 to 6048 per study (<xref rid="app1-pharmacy-13-00021" ref-type="app">Supplementary Table S2</xref>). Ages ranged from 15 to 81 years, although not all studies reported this clearly. Most studies had both male and female participants, except three which had 100% female participants [<xref rid="B22-pharmacy-13-00021" ref-type="bibr">22</xref>,<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>,<xref rid="B24-pharmacy-13-00021" ref-type="bibr">24</xref>]. The race or ethnicity of participants was reported by one study only [<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>].</p><p>Most studies did not present smoking or alcohol use and for those which did, participants were largely non-smokers.</p><p>Most participants were in full-time employment. Education levels were mixed. When relationship status was reported, participants were mainly married, in a relationship/currently partnered and/or living together with their partner.</p><p>Studies categorised the disease type as either UC, CD, IBD, IBD unclassified (IBDU), indeterminate ulcerative colitis (IUC) and unknown, with 2 not reporting the disease type (2.53%) and 34 investigating both CD and UC (43%). A total of 4 studies (5.1%) investigated exclusively CD, whereas 19 (24.1%) focussed on UC. Eighteen studies also categorised IUC or IBDU (22.8%). Two studies did not distinguish between IBD types [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>].</p><p>Time since diagnosis was frequently reported, ranging from 0.1 years to 51 years. A variety of medication classes, routes, regimes and doses were presented, with almost a third included all medication types (27 studies, 34.2%), and 11 (13.9%) not stating this.</p><p>
<bold>Study design</bold>
</p><p>Sixty-six studies (83.5%) were quantitative and ten (12.7%) used mixed methods [<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>]. The remaining three (3.8%) were qualitative [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>], with data analysis following grounded theory principles to develop themes and associated links in one study [<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]. Forty-six studies (58%) were cross-sectional design, through online or face to face questionnaires at a single centre. The remaining study designs were either prospective (10), longitudinal (2), retrospective (12), observational (5), cohort (1) or interviews/focus groups (3). The study length was from 1 month to 13 years. Fifteen studies did not report the length of data collection (see <xref rid="app1-pharmacy-13-00021" ref-type="app">Supplementary Table S3</xref>).</p><p>The <italic toggle="yes">p</italic> values considered as significant were typically &#x0003c;0.05, with either univariate or a range of multivariate analyses conducted.</p><p>A theoretical framework was used by nine studies (11.4%) to explain adherence, their choice of an adherence measure or their findings. </p><p>Quality appraisal rated most studies as medium in quality (36) or high (35), and eight were of low quality. Several studies presented unclear reporting of their results [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B22-pharmacy-13-00021" ref-type="bibr">22</xref>,<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B39-pharmacy-13-00021" ref-type="bibr">39</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>]. </p><p>
<bold>Measuring and Categorisation of Non-adherence</bold>
</p><p>The 79 studies used a wide variety of definitions and tools to measure non-adherence. Consequently, a huge range from 4.3% to 88.9% in non-adherence is presented in <xref rid="pharmacy-13-00021-f001" ref-type="fig">Figure 1</xref>, alongside alternative classifications (when a study used multiple tools for measuring adherence, an overall non-adherence value was calculated). Very few studies found non-adherence to be under 20%.</p><p>Cut-offs for defining adherence/non-adherence were dependent upon the adherence measure used. The most popular cut-off was 80% adherence, whereby non-adherence was taken as the use of equal to [<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>] or less than 80% of the prescribed medication [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>,<xref rid="B43-pharmacy-13-00021" ref-type="bibr">43</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>]. Alternatively, good adherence was defined as taking &#x0003e;80% of the prescribed doses [<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>]. Similarly, if the medication possession ratio (MPR) was &#x02265;80% for an aminosalicylate (5-ASA) treatment, this was frequently rated as good adherence [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>].</p><p>Sub-group analysis of high-quality, multi-centre studies with over 100 participants showed distinct differences between non-adherence rates through validated self-report questionnaires (10.7&#x02013;49.8%) and medication possession ratios (72&#x02013;79%).</p><p>Typically, 21&#x02013;30% of participants were non-adherent to their medication. Ten (12.7%) papers did not report any non-adherence/adherence rates or anything similar [<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>,<xref rid="B45-pharmacy-13-00021" ref-type="bibr">45</xref>,<xref rid="B46-pharmacy-13-00021" ref-type="bibr">46</xref>,<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B48-pharmacy-13-00021" ref-type="bibr">48</xref>,<xref rid="B49-pharmacy-13-00021" ref-type="bibr">49</xref>,<xref rid="B50-pharmacy-13-00021" ref-type="bibr">50</xref>] or were vague in their categorisation, such as &#x0201c;not good adherence&#x0201d; (7%) [<xref rid="B51-pharmacy-13-00021" ref-type="bibr">51</xref>] or &#x0201c;partial non-adherence&#x0201d; at 20% [<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>] or 18% [<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>]. Some authors were consistent in their use of terms, such as &#x0201c;low&#x0201d;, &#x0201c;medium&#x0201d; or &#x0201c;high&#x0201d; non-adherence/adherence, yet studies varied in their definition of these terms, sometimes with minimal or no definition. For example, &#x0201c;low adherence&#x0201d; referred to both 3% [<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>] and 49.8% [<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>] in different studies, whereas &#x0201c;inadequate&#x0201d; adherence in one study included all participants answering &#x0201c;rarely,&#x0201d; &#x0201c;sometimes,&#x0201d; &#x0201c;often&#x0201d; or &#x0201c;always&#x0201d; when asked &#x0201c;How often do you miss medication intake&#x0201d;? [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>]. </p><p>The classification of taking or not taking medication as prescribed was most commonly referred to as &#x0201c;adherence&#x0201d; or &#x0201c;non-adherence&#x0201d; (see <xref rid="app1-pharmacy-13-00021" ref-type="app">Supplementary Table S4</xref>). However, not taking medication as prescribed was occasionally defined as &#x0201c;poor adherence&#x0201d; [<xref rid="B21-pharmacy-13-00021" ref-type="bibr">21</xref>] or &#x0201c;low adherence&#x0201d; [<xref rid="B39-pharmacy-13-00021" ref-type="bibr">39</xref>,<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>], amongst other descriptors. </p><p><xref rid="pharmacy-13-00021-t001" ref-type="table">Table 1</xref> shows the measures of non-adherence reported. Typically, quantitative tools were used. The Morisky medication adherence scale (MMAS) was utilised in 26 studies and author-designed, non-validated questionnaires in 17. Scores on the MMAS often ranged between 4 and 6 out of 8 and were considered as a self-report of &#x0201c;good&#x0201d; adherence. Scoring for validated measures was in line with the recommended guidelines. For example, scoring 4&#x02013;16 out of a possible 20 in the four studies using the medication adherence scale.</p><p>Report Scale-4 (MARS-4) [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B45-pharmacy-13-00021" ref-type="bibr">45</xref>,<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>] was used to assess non-adherence to medication [<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>]. The MARS-5 [<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B48-pharmacy-13-00021" ref-type="bibr">48</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B60-pharmacy-13-00021" ref-type="bibr">60</xref>] and 10-item scale [<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>] were also used, as well as one MARS scale unspecified [<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>]. Additional measures included monitoring of therapeutic drug levels [<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>], medication possession ratio in 14 studies (MPR; percentage of prescribed medication dispensed to a patient during a specific period/over a period of refill intervals) [<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>] and persistence evaluated over one year after an index prescription [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>]. Pill counts over varying time periods [<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>], e.g., two months [<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>], were used in two studies. Sub-group analysis of high-quality studies showed non-adherence ranged from 21.7 to 49.8% when using the validated MMAS measure, whereas this ranged from 10.7 to 28.7% with the MARS measure. Qualitative studies also used a variety of tools to elicit medication concerns [<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]. </p><p>
<bold>Strongest and most consistent associations with non-adherence</bold>
</p><p>Knowledge and understanding of IBD and its treatment had the strongest and most consistent associations with non-adherence, with 92% in the reviewed quantitative studies being significant. Accessibility, organisation and planning were positively correlated with significant results in 80% of investigations using quantitative studies. Qualitative studies also emphasised the impact of forgetting, poor medication availability and disorganisation as the main modifiable non-adherence causes.</p><p>Modifiable treatment-related factors (such as treatment type, route and regimens) were frequently discussed in quantitative and qualitative studies; most were positively associated with non-adherence.</p><p>Modifiable psychological factors were also significantly positively associated with non-adherence in 72% of investigations.</p><p>Several non-modifiable patient demographics were reported in quantitative studies. Most significant was living in poor residential areas, associated with a reduced life quality and socioeconomic status [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B20-pharmacy-13-00021" ref-type="bibr">20</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B45-pharmacy-13-00021" ref-type="bibr">45</xref>,<xref rid="B48-pharmacy-13-00021" ref-type="bibr">48</xref>,<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>]. Finance, medication and increased care cost difficulties were found to be frequently associated with non-adherence risks [<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>,<xref rid="B77-pharmacy-13-00021" ref-type="bibr">77</xref>,<xref rid="B85-pharmacy-13-00021" ref-type="bibr">85</xref>], along with the demographics of age, disease activity and sex.</p><p>
<bold>Factors associated with non-adherence</bold>
</p><p>Within categories associated with non-adherence, specific non-modifiable and modifiable factors were identified throughout the literature. The findings were often contradictory, with minimal agreement, and will be discussed in greater detail.</p><p>Unless otherwise stated, the findings presented are significant under MVA, presented in categories and as individual factors in <xref rid="pharmacy-13-00021-t002" ref-type="table">Table 2</xref> and summarised in the text. The non-adherence risk generally increased with the greater number of significant risk factors experienced [<xref rid="B80-pharmacy-13-00021" ref-type="bibr">80</xref>].</p><p>
<bold>Demographics (non-modifiable):</bold>
</p><p>
<bold>Age</bold>
</p><p>Twenty-four studies reported on age with MVA. There were 15 positive associations with age and non-adherence, 3 mixed (positively and/or negatively associated and non-significant age group dependent), and only 6 non-significant associations in different studies. Participants within the ages of 15&#x02013;29 years were most likely to be non-adherent, while those &#x02265;61 years had greater likelihood of being adherent. Similarly, being below 60 years was also found to be associated with lower adherence compared to over 60 years [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>]. </p><p>
<bold>Age at diagnosis</bold>
</p><p>Four studies explored age at diagnosis in relation to adherence, with mixed findings. Two studies [<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>,<xref rid="B84-pharmacy-13-00021" ref-type="bibr">84</xref>] found that people being diagnosed at a younger age (up to 29 years), were more likely to non-adhere. Yet, two other studies [<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>] reported non-significant results.</p><p>
<bold>Sex</bold>
</p><p>Eleven studies analysed the associations of sex with non-adherence. Females were more likely to be non-adherent in seven studies [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B62-pharmacy-13-00021" ref-type="bibr">62</xref>,<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]. One study reported only females with UC showing higher non-adherence [<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>], whereas another found this for CD [<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>]. Females under 40 years old [<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>] had greatest risk for non-adherence. In contrast, males were significantly more adherent [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>]. However, contradictory findings were also presented in two studies [<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>] with non-adherence higher in males.</p><p>
<bold>Race</bold>
</p><p>Race was only reported in one study [<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>]. Non-adherence was most common in participants of African&#x02013;Caribbean descent, although this was not significant. </p><p>
<bold>Diagnosis (non-modifiable):</bold>
</p><p>Twenty-two studies reported mixed results regarding diagnosis. </p><p>
<bold>Disease type</bold>
</p><p>Eleven studies explored the type of IBD. Four found CD to be associated with non-adherence [<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B60-pharmacy-13-00021" ref-type="bibr">60</xref>,<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>,<xref rid="B91-pharmacy-13-00021" ref-type="bibr">91</xref>], yet five reported this as non-significant [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]. Three studies found UC was not a significant predictor of non-adherence [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>].</p><p>
<bold>Disease activity</bold>
</p><p>Eleven studies investigated disease activity. Participants with active disease were more likely to be non-adherent in three studies [<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]. The relationship between highly active CD and non-adherence through avoiding infusions was associated with pain, diarrhoea or being admitted as an inpatient and receiving alternative treatment [<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]. A negative relationship was reported between active disease and non-adherence in one study [<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>], yet only in patients experiencing at least one relapse in the past 12 months. </p><p>In other studies, participants in remission [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>], those with a lower probability of relapse [<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] or an absence of abdominal symptoms (such as visible bleeding) [<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>] were most likely to be non-adherent. Yet, six studies found these relationships or being in pain due to IBD to be non-significant [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>].</p><p>
<bold>Disease duration</bold>
</p><p>Participants with a &#x0201c;long&#x0201d; diagnosis duration of between 6 and 15 years were reported to be more adherent than those with a shorter diagnosis in a single study [<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>]. Contradicting this, three studies [<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>,<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>] found non-adherence increased with time since diagnosis. Two studies investigated a &#x0201c;short&#x0201d; diagnosis duration of less than 5 years with non-adherence, one finding a significant relationship [<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>] and the other a non-significant one [<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>].</p><p>
<bold>General health (modifiable/non-modifiable)</bold>
</p><p>General health was reported by four studies [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B84-pharmacy-13-00021" ref-type="bibr">84</xref>], with three modifiable and non-modifiable factors related to non-adherence. The most frequent general health risk factor for IBD non-adherence was taking treatment for another chronic condition [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>], with one study finding this to only be significant when the IBD medication was 5-ASA. Having comorbidities was also associated with non-adherence in IBD [<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>].</p><p>Conversely, another study found that individuals not prescribed other chronic treatment were at an up to 2.2 times higher risk of non-adherence with their IBD medication than those who were [<xref rid="B84-pharmacy-13-00021" ref-type="bibr">84</xref>].</p><p>
<bold>Treatment (modifiable)</bold>
</p><p>Treatment, including medication type and mode, route, dose, regimen frequency, convenience of administration and adverse effects, was the most investigated modifiable factor, analysed by MVA in 28 studies with 35 positive relationships with non-adherence.</p><p>
<bold>Drug-Class</bold>
</p><p>Frequently associated with non-adherence was being prescribed either aminosalicylates [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>] or biologics [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>,<xref rid="B87-pharmacy-13-00021" ref-type="bibr">87</xref>,<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>]. Mesalamine was a significant predictor of non-adherence, compared to other drugs [<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>]. One study reported a non-significant relationship between non-adherence and aminosalicylates [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>].</p><p>Patients who had never switched from an index aminosalicylate were much more likely to be non-adherent than those who changed (<italic toggle="yes">p</italic> &#x0003c; 0.0001), with up to 76.9% non-adherence [<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]. Patients with no history of switching from any drug type from their index medication were also likely to be non-adherent [<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>].</p><p>Within different mesalamine types, oral Pentasa had the lowest adherence rate (26.4%), whereas adherence to Mezavant once daily was significantly higher (40.9%) than other oral treatments (<italic toggle="yes">p</italic> &#x0003c; 0.001). Only one study reported lower adherence in patients prescribed non-immunomodulators (<italic toggle="yes">p</italic> = 0.049) than aminosalicylates [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>]. In this study, despite aminosalicylates having the highest non-adherence rates, this was not significant. In the same study [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>], biologics were related to adherent behaviours, supporting other research [<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>].</p><p>Although mixed significant results were also found for biologic medications, if prescribed either biologic/combination biological&#x02013;immunomodulator therapy, this was the only factor associated with low adherence when starting on anti-TNFs in one study [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>] and the single factor correlated with non-adherence in another [<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>]. Regardless of whether patients were treated with biologics intravenously or subcutaneously [<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>,<xref rid="B87-pharmacy-13-00021" ref-type="bibr">87</xref>,<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>], this medication increased the non-adherence risk.</p><p>Four studies found that the prescribed medication type did not have an impact upon non-adherence, whether these were 5-ASAs, biologics, steroids or immunosuppressants [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>] (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p><p>
<bold>Route</bold>
</p><p>Eleven studies investigated the route of administration, with this most frequently relating to higher non-adherence. An uncomfortable medication route, i.e., subcutaneous as opposed to oral treatments [<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>] or via infusion, was associated with not taking it as prescribed [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>]. When patients had never used rectal 5-ASAs, this increased their risk of not taking oral 5-ASA medication [<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>].</p><p>
<bold>Frequency/Regime</bold>
</p><p>Four studies reported the relationship between non-adherence and frequent/multiple medications [<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B79-pharmacy-13-00021" ref-type="bibr">79</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>] or long-term treatments [<xref rid="B62-pharmacy-13-00021" ref-type="bibr">62</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>]. This included initiating treatment on multiple daily dosing of either balsalazide, mesalamine-delayed release (Asacol) or sulfalazine [<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]. A regimen of 40 mg adalimumab every other week was a predictor for missing medication, as opposed to 40 mg weekly. However, increasing adalimumab to 80 mg every other week was a predictor of improved adherence.</p><p>Pill burden (the effort of taking all prescribed drug/s) was a risk for non-adherence in one study [<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>], yet it was also reported as non-significant [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>]. In contrast, when patients were prescribed fewer than eight daily tablets [<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>], non-adherence was increasingly likely. Yet monotherapy was found to have a non-significant effect on non-adherence [<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>].</p><p>
<bold>Side effects</bold>
</p><p>Side effects and non-adherence were reported only by three studies, with a positive relationship in two [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>] and non-significant in one [<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>].</p><p>
<bold>Future non-adherence</bold>
</p><p>Current non-adherence was found to be an independent predictor for future non-adherence [<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>].</p><p>
<bold>Healthcare (modifiable)</bold>
</p><p>Healthcare was frequently investigated for its relationship with non-adherence (17 studies), with 18 modifiable risk factors identified [<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>,<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>,<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]. Non-adherence was most likely when patients experienced negative relations and/or poor communication with healthcare providers [<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>], if no specialist or tailored care was received [<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>] or if frequent inpatient hospitalisation or emergency care was experienced [<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>]. Frequent IBD outpatient [<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>] and general health appointments and adherence monitoring were also associated with adherence promotion [<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>]. The risk of non-adherence significantly increased if a patient received minimal treatment information from their team [<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] or the importance of medication adherence was not reinforced [<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>].</p><p>When patients found contacting their gastroenterologist easy, adherence improved [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>].</p><p>
<bold>Habits (modifiable)</bold>
</p><p>Modifiable habits were investigated by 11 studies, the most common being smoking&#x02014;in 10. Four studies found current smoking to be a non-adherence risk factor [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>,<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>]. In one study, smoking was one of a few significant factors [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>]. Smoking highly influenced non-adherence in specific cohort&#x02014;in patients prescribed thiopurines [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>] or oral 5-ASA [<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>]. Male smokers also showed a significant relationship with non-adherence (<italic toggle="yes">p</italic> = 0.018) [<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>] whereas females did not, with these all being non-smokers. Similarly, another study found non-smoking participants to be more adherent [<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>]. Yet, smoking was not significantly associated with not taking medication in five studies [<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>,<xref rid="B87-pharmacy-13-00021" ref-type="bibr">87</xref>,<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>].</p><p>Alcohol consumption was investigated by two studies, with mixed findings. Consumption (but not frequency) was related to low adherence (<italic toggle="yes">p</italic> = 0.029) in males [<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>]. This was not significant in females [<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>] nor patients overall [<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>]. Prescribed narcotic use was only explored by one study [<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>], with non-significant findings.</p><p>
<bold>Diet (modifiable)</bold>
</p><p>Modifiable dietary factors were reported by four studies. Regularly eating alone [<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>] or missing a meal [<xref rid="B79-pharmacy-13-00021" ref-type="bibr">79</xref>] and not storing medications where meals are eaten [<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>] were all positive predictors of non-adherence. The use of nutritional supplements protected against non-adherence [<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>].</p><p>
<bold>Finance (modifiable/non-modifiable)</bold>
</p><p>Eight studies reported that a mixture of modifiable and non-modifiable financial variables increased non-adherence, specifically having public or non-commercial insurance as opposed to private [<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>,<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>], lower socioeconomic status [<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>] or overall higher healthcare costs (including inpatient, outpatient and emergency) [<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>].</p><p>
<bold>Living location (non-modifiable)</bold>
</p><p>Six studies identified living location as a predictor for non-adherence [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>,<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]. Residing in a socially deprived area and/or reduced life quality significantly predicted non-adherence in all studies that reported this [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>,<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>].</p><p>Country and areas of residence however had mixed results. Living in north-east, south or west America was positively associated with taking medication [<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>], whereas living in the mid-west was not significant [<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]. Residing in the UK over Australia was negatively associated with non-adherence [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>].</p><p>
<bold>Employment (non-modifiable)</bold>
</p><p>Five studies investigated employment. Demanding, busy work constraints relating to treatment increased non-adherence [<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>]. Full-time employment and/or a greater number of working hours were also positively associated with non-adherence [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>].</p><p>&#x0201c;Permanent employment&#x0201d;, however, was not significantly correlated with non-adherence [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>], and &#x0201c;self-employment&#x0201d; reduced the risk of non-adherence [<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>].</p><p>
<bold>Education (non-modifiable)</bold>
</p><p>Five studies reported on education level and its impact upon taking medication [<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>]. Those with a combined higher socioeconomic status, occupational and educational level were more non-adherent, but they were not significant as individual factors in the same study [<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>].</p><p>
<bold>Social support and relationships (modifiable/non-modifiable)</bold>
</p><p>Five studies investigated social support and relationships [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]. Non-adherence was associated with being single [<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>] or receiving poor social support, whether emotional or tangible [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>] or low informational social support [<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>]. Having to &#x0201c;deal with friends&#x0201d; when living with CD in fact increased the risk of non-adherence, but not in UC [<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>].</p><p>
<bold>Psychological factors (modifiable)</bold>
</p><p>Psychological health was one of the most frequently modifiable factors investigated, but with contradictory results. Twenty-five studies were carried out, with treatment beliefs, perceptions and concerns explored in seventeen studies. Negative beliefs, mediated by poor patient satisfaction, led to low adherence [<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>]. When treatment was thought ineffective [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>] or unnecessary by the patient [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>], this was also positively related to non-adherence (seven studies). Conversely, when individuals expressed a need for their IBD treatment, this was protective against non-adherence [<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>]. Disease beliefs were also significantly related to non-adherence&#x02014;specifically when IBD was perceived as having a short illness duration [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B64-pharmacy-13-00021" ref-type="bibr">64</xref>], with one study finding significance only for participants with CD [<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>]. A weaker illness identity (fewer IBD associated symptoms) was also a risk for low adherence [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>], although the illness perceptions of the daily consequences of living with IBD were not [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>].</p><p>Treatment concerns, namely side [<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>] and adverse effects [<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>], predicted low medication adherence (in three studies), regardless of medication type. However, this was non-significant in four studies [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>].</p><p>When participants expressed a reduced sense of control over their IBD [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>], lower perceived competence with treatment regime [<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>] or experienced religious or spiritual struggle using negative coping strategies [<xref rid="B46-pharmacy-13-00021" ref-type="bibr">46</xref>], non-adherence increased.</p><p>Nine studies researched depression and poor psychological states, seven of which identified these as significant non-adherence risks [<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>,<xref rid="B92-pharmacy-13-00021" ref-type="bibr">92</xref>].</p><p>Anxiety was a significant risk for non-adherence in all four studies investigating this factor [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>]. When UC had less of an impact on an individual&#x02019;s mood [<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>] or the patient was indifferent or sceptical regarding treatment benefit [<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>], these were largely predictive of non-adherence. Experiencing a stronger, negative emotional response to having IBD [<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>] was also associated with not taking medication as prescribed. Only one study found mood did not influence adherence [<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>].</p><p>
<bold>Accessibility, organisation and planning (modifiable)</bold>
</p><p>Ten studies reported on personal awareness and planning [<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>,<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>]. Missing scheduled appointments [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>], having a lower priority for medications [<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>], not being as careful when taking medications [<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>] and medication doses at weekends [<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>] were found to be significant non-adherence predictors. Not using tools such as dosette boxes or cues to action, e.g., alarms or reminders to take medication, whether from family or healthcare providers, was also a risk for non-adherence [<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>]. Mixed evidence was found for forgetting or carelessness and not keeping medications accessible when due, reporting both significantly positive [<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>] and non-significant [<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>] relationships with not taking medication.</p><p>
<bold>Knowledge and understanding (modifiable)</bold>
</p><p>This was investigated by 12 studies, with 10 showing positive associations with non-adherence [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>]. Having poor disease or treatment knowledge [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>] or limited medical information recall [<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>] was related to non-adherence. Yet one study found this only in UC patients [<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>] and another only for knowledge of azathioprine [<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>]. These factors were also related with non-adherence when participants reported poor communication with [<xref rid="B39-pharmacy-13-00021" ref-type="bibr">39</xref>] or inadequate medication information from healthcare professionals [<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>].</p><p>Not being keen on using the internet [<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>] was a significant risk for non-adherence, whereas having &#x0201c;high curiosity levels&#x0201d; [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>] was not.</p><p>Patient organisation membership increased adherence in one study [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>] and increased non-adherence in another [<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>].</p><p>
<bold>Alternative treatment (modifiable)</bold>
</p><p>Of two studies investigating alternative and complementary therapies, one found patients seeking holistic health approaches to be more likely to reduce prescribed IBD medication, as compared to those who did not (30% vs. 16%, <italic toggle="yes">p</italic> = 0.02) [<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>]. Yet individuals using complementary therapies for general health showed similar non-adherence to those using prescribed medications. Complementary therapy use for IBD was also non-significant [<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>].</p><p>
<bold>Specific cohorts (non-modifiable)</bold>
</p><p>Cohort specific factors investigated included pregnant and post-partum women [<xref rid="B22-pharmacy-13-00021" ref-type="bibr">22</xref>,<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>,<xref rid="B24-pharmacy-13-00021" ref-type="bibr">24</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>], with no studies specifically analysing non-adherence risk at the MVA level. However, non-adherence led to a significantly increased likelihood for disease relapse and adverse pregnancy outcomes at the MVA level, particularly in women taking oral mesalamine [<xref rid="B24-pharmacy-13-00021" ref-type="bibr">24</xref>].</p><p>Two studies researched non-adherence throughout the COVID-19 pandemic; again, there were none at the MVA level [<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>]. The greatest non-adherence reason was fear of attending hospital (50% participants), due to the perception of catching infections because of their IBD, being immunosuppressed [<xref rid="B77-pharmacy-13-00021" ref-type="bibr">77</xref>] or having higher medication concerns [<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>].</p><p>
<bold>Qualitative studies</bold>
</p><p>Thirteen studies presented qualitative data, three were purely qualitative [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>], and nine predominantly quantitative with free text comments [<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>] (<xref rid="pharmacy-13-00021-t003" ref-type="table">Table 3</xref>).</p><p>Reported reasons for non-adherence, are presented in themes (<xref rid="pharmacy-13-00021-t004" ref-type="table">Table 4</xref>), with direct quotations (<xref rid="pharmacy-13-00021-t005" ref-type="table">Table 5</xref>).</p><p>
<bold>Treatment</bold>
</p><p>The most frequent type of treatment adherence barriers expressed were adverse effects [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]. Uncertainty regarding drug safety was also common [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>].</p><p>The administration mode [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>], including rectal [<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>], and self-administered subcutaneous injections, was reported as a challenge [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]. Several drugs taken multiple times a day were considered to pose treatment difficulties, resulting in &#x0201c;pill fatigue&#x0201d; [<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]. A desire for a &#x0201c;simpler regimen&#x0201d; [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>] was often expressed.</p><p>
<bold>Finance</bold>
</p><p>Repeated prescription costs were also reported as a non-adherence reason [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>].</p><p>
<bold>Lifestyle</bold>
</p><p>Travelling and/or being in public spaces [<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>] with busy lifestyles were problematic for adhering. This included carrying medications to work [<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>] or difficulties renewing prescriptions when away from home [<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>].</p><p>
<bold>Beliefs</bold>
</p><p>Personal opinions regarding treatment necessity often influenced medication discontinuation, altering doses and missing intermittent ones [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]. Reasons also included non-acceptance of diagnosis, leading to a negative emotional response towards treatment [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>].</p><p>
<bold>Forgetting and Organisation</bold>
</p><p>Forgetting was a main reason for not taking medications [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]. Timing with due treatment or general disorganisation were also adherence barriers [<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>].</p><p>
<bold>Accessibility</bold>
</p><p>Accessing medications was a common adherence challenge [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>], as was repeatedly refilling medications [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>].</p><p>
<bold>Pregnancy and pregnancy planning</bold>
</p><p>Being pregnant and avoiding harm to the baby was a frequent concern of women using a range of medications [<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]. Women also spoke about safety and uncertainty of teratogenic effects if currently pregnant or planning pregnancy, in addition to fertility concerns from females and males [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>].</p></sec><sec sec-type="discussion" id="sec4-pharmacy-13-00021"><title>4. Discussion</title><p>This is the most recent comprehensive international review that outlines the complexities and challenges of non-adherence to prescribed medication in IBD today. Between 4.3% to 88.9% of patients were identified to be non-adherent, with at least 30% in most studies and a lack of consensus on defining adherence/non-adherence [<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>,<xref rid="B87-pharmacy-13-00021" ref-type="bibr">87</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]. The large range of adherence cut-offs, depending upon the instrument&#x02019;s purpose [<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>], maximised differences between adherent and non-adherent IBD patients, potentially leading to inaccurate measurement of these concepts. Multiple versions of the same tool to measure adherence made study comparisons difficult.</p><p>Individual studies suggest adherence rates differ due to a range of complex, modifiable and non-modifiable factors that could be intentional and/or unintentional [<xref rid="B87-pharmacy-13-00021" ref-type="bibr">87</xref>]. Interestingly, the majority of reviewed studies did not measure &#x0201c;intentional&#x0201d; or &#x0201c;unintentional&#x0201d; concepts or explore the reasoning behind non-adherence. Consequently, a large, inconsistent, often poorly reported and contradictory set of literature exists, making it challenging to draw specific clinical conclusions from this review.</p><p>Knowledge and understanding of IBD and its treatment were the most frequent modifiable predictors of non-adherence, with 92% of associations in the reviewed quantitative studies being significant for non-adherence. Low disease knowledge can be influenced by diagnosis uncertainty [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>], leading to classification bias for patients and research. This review included CD, UC and indeterminate colitis and their range of treatments, which were not wholly comparable. Agreed validated international case definitions for IBD are required to clarity patient understanding whilst minimising the risk of misclassification, impact upon non-adherence and data misinterpretation [<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>].</p><p>Lack of understanding of IBD and medication benefits [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>], common in newly diagnosed patients, can significantly impact non-adherence. Improved patient understanding of the disease and the need for continuous medication requires clear, concise education regarding IBD and its treatment, provided by multidisciplinary teams [<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>]. If not delivered effectively by specialist clinicians [<xref rid="B96-pharmacy-13-00021" ref-type="bibr">96</xref>], IBD patients may recall only 50% of information from appointments [<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>]. This can lead to poor adherence soon after the first consultation [<xref rid="B48-pharmacy-13-00021" ref-type="bibr">48</xref>], meaning the reinforcement of key medication messages is critical. Also vital at the treatment recommendation stage is determining the likelihood of patients taking medication. This will allow the clinician to work through together with the patient to target any challenges or barriers. Socratic questioning to elicit personal circumstances together with Motivational Interviewing techniques such as &#x0201c;How likely are you to take your medication?&#x0201d; and &#x0201c;What would help you in taking it?&#x0201d; have been shown to be particularly effective [<xref rid="B97-pharmacy-13-00021" ref-type="bibr">97</xref>].</p><p>The impact of self-education is inconsistent [<xref rid="B98-pharmacy-13-00021" ref-type="bibr">98</xref>], as this review shows it may not facilitate adherence [<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>]. Patients have a desire for self-teaching surrounding their long-term condition and medication-related knowledge [<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>]. Internet use is popular to support active learning, promote disease understanding and evaluate medical advice, but has the potential to be inaccurate and/or misleading and may not fully meet patients&#x02019; expectations, leading to poorer adherence [<xref rid="B99-pharmacy-13-00021" ref-type="bibr">99</xref>]. Furthermore, adherence research using the internet may exclude those without access. Alternatively, when healthcare professionals take time to provide accurate guidance, patients can feel more confident about managing their IBD [<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>], reducing their anxiety and encouraging more timely follow-ups [<xref rid="B100-pharmacy-13-00021" ref-type="bibr">100</xref>]. Yet, clinicians must remain mindful of knowledge and understanding developing within the same individual through experience, potentially impacting upon adherence changes [<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>]. This demands a need for personalised educational interventions, rather than generic solutions [<xref rid="B43-pharmacy-13-00021" ref-type="bibr">43</xref>], for adherence promotion [<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>].</p><p>Accessibility, organisation and planning were positively correlated with significant results in 80% of investigations by quantitative studies. Qualitative studies emphasised the impact of forgetting, poor medication availability and disorganisation as the main modifiable non-adherence causes. Lack of routine, busy lifestyles, including full-time employment [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>] and medication regimes interfering with daily activities commonly increase the likelihood of forgetting, leading to non-adherence [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B43-pharmacy-13-00021" ref-type="bibr">43</xref>,<xref rid="B79-pharmacy-13-00021" ref-type="bibr">79</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>], particularly if lower treatment priority is expressed. Forgetting can be effectively modified with strategies such as setting alarms and placing medication close to traditional reminders (e.g., toothbrush or kettle) [<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>,<xref rid="B101-pharmacy-13-00021" ref-type="bibr">101</xref>]. Reminders and feedback from healthcare professionals can also be an effective, inexpensive method to enhance clinical practice and medication use [<xref rid="B12-pharmacy-13-00021" ref-type="bibr">12</xref>,<xref rid="B17-pharmacy-13-00021" ref-type="bibr">17</xref>,<xref rid="B102-pharmacy-13-00021" ref-type="bibr">102</xref>]. Memory cues help to prevent a diminished sense of treatment priority [<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>]. Medication dispensers or pill cases are reportedly strongest at predicting good adherence [<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>], easily determining whether medication has been taken. Adherence interventions containing such technical components have demonstrated consistent benefits over time [<xref rid="B103-pharmacy-13-00021" ref-type="bibr">103</xref>]. Reward approaches have also shown improvements when combined with these technical strategies, although further research is recommended [<xref rid="B104-pharmacy-13-00021" ref-type="bibr">104</xref>].</p><p>Modifiable treatment-related factors were frequently discussed in quantitative and qualitative studies, most were positively associated with non-adherence. IBD has the complexity of multiple medications, supplements and variable regimes, which can significantly impact non-adherence&#x02014;found in some studies to be almost 90% [<xref rid="B105-pharmacy-13-00021" ref-type="bibr">105</xref>]. Medication side effects [<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B105-pharmacy-13-00021" ref-type="bibr">105</xref>] also significantly determine adherence, potentially increasing the use of &#x0201c;complementary and alternative medicine.&#x0201d;</p><p>IBD treatment administered via various routes [<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>] may cause discomfort (e.g., injections, rectal medications or oral tablets that are difficult/large to swallow) and may be associated with greater non-adherence risks [<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>], impacting life quality [<xref rid="B43-pharmacy-13-00021" ref-type="bibr">43</xref>]. Yet despite this, some non-adherence data collection tools are designed solely for one medication route and/or type [<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>]. Furthermore, techniques such as MPR have been identified to have variable calculation methods, significantly affecting adherence estimates [<xref rid="B106-pharmacy-13-00021" ref-type="bibr">106</xref>]. Thus, the validity and verifiability of study results should be interpreted with caution. A variety of methods collecting a combination of adherence barriers and disease activity have been suggested, although data interpretation gathered from a range of approaches can be challenging, increasing the potential for disagreement.</p><p>Non-adherence to oral 5-ASA was frequent in this review [<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>], correlating with previous reports [<xref rid="B51-pharmacy-13-00021" ref-type="bibr">51</xref>,<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>] ranging from 38 to 60% [<xref rid="B107-pharmacy-13-00021" ref-type="bibr">107</xref>]. Prescribed for less severe, more stable disease, this requires minimal monitoring, often leading to greater non-adherence [<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]. Patients typically identify quiescent periods with recovery, with a reduced need for treatment [<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B76-pharmacy-13-00021" ref-type="bibr">76</xref>]. Aminosalicylates are also associated with decreased frequency and dosing, with monotherapy reporting higher non-adherence rates, as opposed to combination therapy [<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>]. Monitoring adherence using targeted strategies in stable patients is therefore necessary [<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>].</p><p>Other IBD medications taken infrequently (e.g., immunosuppressants) necessitate specific storage and/or require attendance to hospital appointments for administration, raising non-adherence risks [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]. Conversely, multiple inconvenient dosing regimens influence developing routines and habits [<xref rid="B43-pharmacy-13-00021" ref-type="bibr">43</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>,<xref rid="B64-pharmacy-13-00021" ref-type="bibr">64</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>]. Similarly, previous literature reported 30% of patients when asked reasons for non-adherence, answered &#x0201c;<italic toggle="yes">too many pills</italic>&#x0201d; [<xref rid="B10-pharmacy-13-00021" ref-type="bibr">10</xref>]. Despite a long-established inverse relationship between the dosing regimen complexity and non-adherence in IBD [<xref rid="B101-pharmacy-13-00021" ref-type="bibr">101</xref>,<xref rid="B108-pharmacy-13-00021" ref-type="bibr">108</xref>], complicated &#x0201c;three times daily&#x0201d; dosing regimens are still used by many gastroenterologists [<xref rid="B64-pharmacy-13-00021" ref-type="bibr">64</xref>]. To achieve better clinical IBD outcomes, the findings from this review and prior evidence support simplifying daily regimes wherever possible [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B68-pharmacy-13-00021" ref-type="bibr">68</xref>,<xref rid="B79-pharmacy-13-00021" ref-type="bibr">79</xref>].</p><p>Patient preferences must be identified in both clinical prescribing and reversed supervision (prospective prescriptions considering individual retrospective medication adherence) [<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B43-pharmacy-13-00021" ref-type="bibr">43</xref>]. For research, specific aims investigating single medication regimes in one chronic disease is encouraged, to more accurately identify non-adherence predictors [<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>].</p><p>Modifiable psychological factors were significantly positively associated with non-adherence in 72% of investigations, supporting previous systematic reviews [<xref rid="B16-pharmacy-13-00021" ref-type="bibr">16</xref>,<xref rid="B17-pharmacy-13-00021" ref-type="bibr">17</xref>]. Depression was the most common, followed closely by anxiety, then patients less bothered about the treatment benefit or their IBD having a lower impact on mood. Depression is a risk in many chronic disease populations [<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B109-pharmacy-13-00021" ref-type="bibr">109</xref>,<xref rid="B110-pharmacy-13-00021" ref-type="bibr">110</xref>], frequently associated with stress, &#x0201c;feeling hassled&#x0201d; and significant life events, together possibly contributing to non-adherence and IBD relapse [<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B111-pharmacy-13-00021" ref-type="bibr">111</xref>]. Concerns regarding medication safety and adverse effects regarding long-term maintenance medication [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>,<xref rid="B10-pharmacy-13-00021" ref-type="bibr">10</xref>,<xref rid="B107-pharmacy-13-00021" ref-type="bibr">107</xref>] cause further treatment stressors and &#x0201c;adherence barriers&#x0201d; [<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>].</p><p>Purposefully not taking prescribed medication can often be the main reason for intentional non-adherence. Ranging from 70.7 to 97%, it is typically higher than non-intentional non-adherence, associated with treatment doubts when feeling well and/or not experiencing effective action, particularly if an individual considers that the treatment disadvantages outweigh the benefits [<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>]. This perception of the necessity for medication can be impacted by prior experiences, with the importance of necessity reducing over time [<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>].</p><p>Yet voluntary non-adherence is more challenging to address. These non-adherence difficulties may not be disclosed to healthcare professionals [<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>], particularly if negative relations exist involving poor communication [<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>] and a lack of specialist healthcare [<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]. This review and previous studies and reviews found such modifiable healthcare factors positively associated with non-adherence [<xref rid="B16-pharmacy-13-00021" ref-type="bibr">16</xref>]. To promote good patient&#x02013;physician relations, reinforcing empathy and leniency is recommended [<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>]. This helps by avoiding putting patients in a defensive state when asking them to self-report adherence behaviours, achieving honest, reliable answers [<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>]. Despite this, it is argued that most people report the truth when questioned about their adherence [<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>]. Many studies conclude that the combined use of self-reporting along with a more validated, objective adherence measurement is appropriate for a greater understanding of non-adherence reasons [<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B43-pharmacy-13-00021" ref-type="bibr">43</xref>,<xref rid="B48-pharmacy-13-00021" ref-type="bibr">48</xref>,<xref rid="B77-pharmacy-13-00021" ref-type="bibr">77</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>,<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>].</p><p>Once non-adherence is identified, intervention strategies must actively involve those patients choosing not to take IBD medication as prescribed [<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>], promoting their awareness of the non-adherence consequences [<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>,<xref rid="B24-pharmacy-13-00021" ref-type="bibr">24</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>]. When individuals view their medications more positively, they are more likely to adhere to it [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>]. However, this tailored approach in specialist healthcare with overstretched services could be challenging. To ensure that the care needs of people with IBD are focussed upon [<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>], a balanced approach with multidisciplinary teams supporting patients to access offline/online resources [<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>,<xref rid="B109-pharmacy-13-00021" ref-type="bibr">109</xref>], offering accurate, comprehensive and holistic IBD education, will subsequently help to promote knowledge and self-management [<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>].</p><p>Several non-modifiable patient demographics were reported in quantitative studies. Most significant was living in poor residential areas, associated with reduced life quality and socioeconomic status [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>,<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]. Finance, medication and increased care cost difficulties also indirectly impact psychological stability and adherence [<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>], referred to as &#x0201c;downstream non-adherence consequences&#x0201d; [<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>], rather than being direct predictors [<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>]. Further research is warranted to explore these complex contributory factors to non-adherence [<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>].</p><p>Age, disease activity and sex were non-modifiable demographics associated with significant non-adherence risks. Yet age and disease activity were also not significant in some studies, supporting the previous inconsistent literature [<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>]. Younger people do not necessarily prioritise medication use, focussing upon leisure, going out and friendships [<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>] as opposed to discussing health conditions and concerns with others [<xref rid="B107-pharmacy-13-00021" ref-type="bibr">107</xref>]. The contradictory results for these factors could be attributed to the high levels of heterogeneity in the studies compared. Most specifically, methodological weaknesses were brought about by many smaller, single-site, retrospective studies with lower sample sizes. Additional sub-group analysis of specific data highlighted the limitations of comparing multiple adherence measurements across a range of studies, namely self-report and medication refills. As secondary measures of adherence, medication refills are a popular, relatively straightforward method for avoiding the subjective bias of inaccurate patient recall. However, they have been known to inaccurately estimate adherence and it is impossible to determine whether a patient has accurately taken their medication [<xref rid="B112-pharmacy-13-00021" ref-type="bibr">112</xref>]. The PDC is considered a more accurate, suitable method, focusing on days the patient is &#x0201c;covered&#x0201d; or supplied with medication [<xref rid="B113-pharmacy-13-00021" ref-type="bibr">113</xref>].</p><p>Simple, universal interventions for these non-modifiable factors reflect similar outcomes, often producing non-significant improvements in non-adherers [<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>]. Special care should be taken to increase medication adherence in youngsters with IBD [<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>], particularly with IBD incidence in adolescents increasing [<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>]. Younger patients need support to modify their treatment, thought processes on adherence and non-adherence consequences [<xref rid="B46-pharmacy-13-00021" ref-type="bibr">46</xref>]. Simpler drug delivery regimes whilst monitoring patients are beneficial [<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>], combined with supervised, smooth care transitions to adult services [<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>].</p><p>Specifically, the non-adherence in young females with IBD identified in this review [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>] is consistent with previous findings [<xref rid="B110-pharmacy-13-00021" ref-type="bibr">110</xref>]. Social embarrassment of IBD and enema use are suggested reasons [<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B111-pharmacy-13-00021" ref-type="bibr">111</xref>]. As IBD patients are largely affected during child-bearing age, females frequently express treatment concerns specific to reproductive journeys, fertility, pregnancy and lactation fears, leading to non-adherence [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>,<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B114-pharmacy-13-00021" ref-type="bibr">114</xref>], verified by qualitative data. Previous research shows pregnant women often overestimate the potential harm of their IBD medication, with many of those choosing to breastfeed discontinuing treatment (74%) [<xref rid="B115-pharmacy-13-00021" ref-type="bibr">115</xref>]. Enhancing the quality and quantity of accurate, accessible reproductive health and IBD information available for patients is necessary, as opposed to potentially seeking limited, non-evidence-based information online [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]. Timely, bespoke reproductive counselling from gastroenterologists, reinforcing importance of adherence before, during and after pregnancy is effective [<xref rid="B114-pharmacy-13-00021" ref-type="bibr">114</xref>]. This close working of clinician and patient in a supported, communicative manner bridges vital information gaps in reproductive health and IBD whilst reducing flare-ups and modifying non-adherence [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>].</p><p>
<bold>Strengths and Limitations</bold>
</p><p>The literature for this review spans 12 years, identified from a broad range of extensive databases representing medical, nursing, health, psychology and scientific disciplines, from clinical, academic and research data. With healthcare changing rapidly, variability is huge across the identified studies. The selected period allows a consideration of the unprecedented, life-changing experiences (e.g., COVID-19 pandemic, cost of living crisis) [<xref rid="B77-pharmacy-13-00021" ref-type="bibr">77</xref>] which critically impacted medication use and data collection. However, these times may also limit accuracy and generalisability. Considering such prior practice may be incompatible, opposing current patient care, particularly following the pandemic or immunomodulator use [<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>].</p><p>This international literature review considered a huge variety of factors including healthcare, cultures, insurance, prescribing and medications, clinic and medication accessibility, availability and disease-related knowledge [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B21-pharmacy-13-00021" ref-type="bibr">21</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B76-pharmacy-13-00021" ref-type="bibr">76</xref>], enhancing generalisability. These must be considered when investigating non-adherence in patients.</p><p>Yet, cross-continental comparison of the same medication type incorporates national drug variations due to formulations, prescribing practices, treatment availability, diverse patient-funding of prescriptions and biased patient profiles [<xref rid="B21-pharmacy-13-00021" ref-type="bibr">21</xref>,<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B50-pharmacy-13-00021" ref-type="bibr">50</xref>]. Additional difficulties arise when validated tools are translated into alternative languages, with assorted interpretations. A range of adherence and non-adherence terms being used synonymously across the literature adds further interpretative complexity. Non-adherence rates may also be determined by the adherence measure/s used, which may not be wholly comparable.</p><p>The review inclusion criteria were pre-defined but generous, with no design restrictions, resulting in a large quantity of studies, varied patient cohorts and study designs. However, this led to challenges in synthesising data. Overall, a large sample [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>,<xref rid="B114-pharmacy-13-00021" ref-type="bibr">114</xref>] more accurately represents the adherence of general populations in real-world clinical settings as opposed to clinical trials. Yet this is limited by minimal demographic data collection [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]. Individually, many studies had the strengths of focussing upon &#x0201c;select cohorts,&#x0201d; particularly those who were non-adherent [<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>], from single centres [<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B22-pharmacy-13-00021" ref-type="bibr">22</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>,<xref rid="B39-pharmacy-13-00021" ref-type="bibr">39</xref>,<xref rid="B45-pharmacy-13-00021" ref-type="bibr">45</xref>,<xref rid="B46-pharmacy-13-00021" ref-type="bibr">46</xref>,<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B51-pharmacy-13-00021" ref-type="bibr">51</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B61-pharmacy-13-00021" ref-type="bibr">61</xref>,<xref rid="B62-pharmacy-13-00021" ref-type="bibr">62</xref>,<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>,<xref rid="B64-pharmacy-13-00021" ref-type="bibr">64</xref>,<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>,<xref rid="B68-pharmacy-13-00021" ref-type="bibr">68</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>,<xref rid="B77-pharmacy-13-00021" ref-type="bibr">77</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>,<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>,<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>,<xref rid="B84-pharmacy-13-00021" ref-type="bibr">84</xref>,<xref rid="B87-pharmacy-13-00021" ref-type="bibr">87</xref>,<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>,<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>,<xref rid="B91-pharmacy-13-00021" ref-type="bibr">91</xref>,<xref rid="B92-pharmacy-13-00021" ref-type="bibr">92</xref>], typically outpatient or tertiary [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>,<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B22-pharmacy-13-00021" ref-type="bibr">22</xref>,<xref rid="B24-pharmacy-13-00021" ref-type="bibr">24</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B43-pharmacy-13-00021" ref-type="bibr">43</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>,<xref rid="B46-pharmacy-13-00021" ref-type="bibr">46</xref>,<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B51-pharmacy-13-00021" ref-type="bibr">51</xref>,<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B62-pharmacy-13-00021" ref-type="bibr">62</xref>,<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B77-pharmacy-13-00021" ref-type="bibr">77</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>,<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>,<xref rid="B84-pharmacy-13-00021" ref-type="bibr">84</xref>,<xref rid="B87-pharmacy-13-00021" ref-type="bibr">87</xref>,<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>,<xref rid="B92-pharmacy-13-00021" ref-type="bibr">92</xref>], with small samples [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>,<xref rid="B24-pharmacy-13-00021" ref-type="bibr">24</xref>,<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>,<xref rid="B68-pharmacy-13-00021" ref-type="bibr">68</xref>,<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>,<xref rid="B85-pharmacy-13-00021" ref-type="bibr">85</xref>]. However, such literature may not generate &#x0201c;meaningful&#x0201d; results [<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>]. Future research acknowledges a need for replication with larger, more diverse samples from multi-centres [<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>] and extended follow-ups, enhancing representation whilst increasing validity [<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>].</p><p>58%of the reviewed studies were cross-sectional in design [<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B21-pharmacy-13-00021" ref-type="bibr">21</xref>,<xref rid="B22-pharmacy-13-00021" ref-type="bibr">22</xref>,<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B39-pharmacy-13-00021" ref-type="bibr">39</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>,<xref rid="B45-pharmacy-13-00021" ref-type="bibr">45</xref>,<xref rid="B46-pharmacy-13-00021" ref-type="bibr">46</xref>,<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B49-pharmacy-13-00021" ref-type="bibr">49</xref>,<xref rid="B50-pharmacy-13-00021" ref-type="bibr">50</xref>,<xref rid="B51-pharmacy-13-00021" ref-type="bibr">51</xref>,<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B61-pharmacy-13-00021" ref-type="bibr">61</xref>,<xref rid="B62-pharmacy-13-00021" ref-type="bibr">62</xref>,<xref rid="B64-pharmacy-13-00021" ref-type="bibr">64</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B68-pharmacy-13-00021" ref-type="bibr">68</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>,<xref rid="B76-pharmacy-13-00021" ref-type="bibr">76</xref>,<xref rid="B77-pharmacy-13-00021" ref-type="bibr">77</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>,<xref rid="B79-pharmacy-13-00021" ref-type="bibr">79</xref>,<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>,<xref rid="B92-pharmacy-13-00021" ref-type="bibr">92</xref>], typically at a single timepoint, over short periods, meaning it was impossible to evaluate the suggested strategies for adherence promotion [<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>]. Longitudinal studies have challenges regarding pharmacy medication records maintaining accuracy and consistency. Studies presenting retrospective research [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>] are limited to previous behaviours. To predict future non-adherence and evaluate strategies for adherence promotion, further prospective research is necessary [<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>].</p><p>A specific study limitation identified from this review and earlier research [<xref rid="B114-pharmacy-13-00021" ref-type="bibr">114</xref>], was the restricted inclusion criteria, with some studies only including participants of a certain diagnosis length [<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>,<xref rid="B50-pharmacy-13-00021" ref-type="bibr">50</xref>]. This may minimise the influence of disease duration, shown to impact IBD non-adherence [<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>,<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>]. Using only papers published in English and with methodological differences of selection [<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>] restricts the representativeness, generalisability and persuasiveness to community practice.</p><p>Biases also arose from the investigation of specific adherence-related factors [<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>], with some studies failing to report on known risks (e.g., smoking, body mass index, employment or socioeconomic status) [<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>] or the reasoning for non-adherence [<xref rid="B24-pharmacy-13-00021" ref-type="bibr">24</xref>].</p><p>The analysis of this review was thorough and detailed, considering both qualitative and quantitative studies. Focussing on significance at a multivariate level ensured confounding factors were eliminated, whilst identifying those most likely related to non-adherence.</p><p>Finally, a main limitating challenge within all adherence data is the true prevalence rate [<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>]. Typically, non-adherers are the least likely to participate in research or attend clinics [<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>], potentially masking and underrepresenting their perspectives, trends and behaviours. Moving forward, utilising accurate prescription databases with more clinical data collection may overcome this, comparing responders with non-responders [<xref rid="B114-pharmacy-13-00021" ref-type="bibr">114</xref>].</p></sec><sec sec-type="conclusions" id="sec5-pharmacy-13-00021"><title>5. Conclusions</title><p>Treatment adherence is a critical component in maintaining remission, alongside other clinical and biological factors. This review has identified many modifiable and non-modifiable factors having mixed relationships with non-adherence in IBD, thus offering an improved understanding of determinants of adherence and non-adherence.</p><p>In future practice, multidisciplinary clinicians must collaborate with patients throughout their IBD journey. Firstly, identifying barriers and challenges patients foresee regarding taking their IBD medication through active listening and questioning. Clinicians aware of non-modifiable factors can better identify patients at risk of non-adherence and develop targeted strategies to support them. Problem solving targeting modifiable adherence barriers could reverse and modify active patient decisions of not taking treatment.</p><p>Unrealistic modifiable medication fears must be addressed through education to enable clear knowledge and understanding of IBD and treatment. Healthcare professionals should enhance patients&#x02019; self-management strategies, offering accurate resources for independent learning. Various technical and reward strategies could be suggested to patients to improve their organisation and planning of treatment taking. Ongoing patient monitoring of the psychological and physical impact of IBD with personalised adherence support is required. A &#x0201c;one-size-fits-all&#x0201d; approach must be avoided, as the underlying causes and common barriers may differ considerably, necessitating varied interventions.</p><p>For future research, a unified, formalised definition of non-adherence is urgently needed, with consideration of how theoretical models of adherence could inform future research. This will help to further clarify between intentional and non-intentional non-adherence and modifiable and non-modifiable factors. It is critical to utilise a range of measures to help to determine objective, accurate non-adherence rates. Additional qualitative investigations will also identify reasoning behind non-adherent behaviours.</p><p>Further investigation of adherence promotion interventions tailored to the most salient non-adherence risk factors including knowledge and understanding of IBD and treatment, accessibility, organisation and planning, forgetting, poor medication availability, treatment-related factors (type, route and regimens) and modifiable psychological factors is also critical. Specifically, further research to minimise forgetting and regarding the impact of reward strategies is warranted.</p><p>Informed development and implementation of adherence support programmes will ultimately improve individual health outcomes, quality of life and health-related costs.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to express gratitude to the Research Placement Student Awa Jammeh for her contribution to <xref rid="pharmacy-13-00021-f001" ref-type="fig">Figure 1</xref> development and referencing.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmacy-13-00021"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmacy13010021/s1">https://www.mdpi.com/article/10.3390/pharmacy13010021/s1</uri>, Figure S1: PRISMA flow diagram, selection of studies for systematic review&#x02014;Supplementary Figure S1 outlines the process of selection for identified, screened and included studies for the systematic review; Table S1a: Key search terms&#x02014;Supplementary Table S1a presents the full list of key search terms used for the database searching of relevant articles; Table S1b: Search strategy for all databases&#x02014;Supplementary Table S1b presents the search strategy applied for all databases; Table S2: Patient demographics&#x02014;Supplementary Table S2 shows the demographical data of participants from the reviewed studies; Table S3: Study design&#x02014;Supplementary Table S3 presents the study designs of all the studies reviewed; Table S4: Categorisation and measuring non-adherence&#x02014;Supplementary Table S4 lists the terminology used when describing non-adherence, non-adherence measures, non-adherence cut-offs in quantitative studies and the percentage of non-adherence within each reviewed study.</p><supplementary-material id="pharmacy-13-00021-s001" position="float" content-type="local-data"><media xlink:href="pharmacy-13-00021-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualisation, K.K., C.N. and W.C.-D.; methodology, K.K., C.N. and W.C.-D.; software, K.K. and C.N.; validation, K.K., C.N. and W.C.-D.; formal analysis, K.K., C.N. and W.C.-D.; investigation, K.K. and C.N.; resources, K.K. and C.N.; data curation, K.K. and C.N.; writing&#x02014;original draft preparation, K.K.; writing&#x02014;review and editing, K.K., C.N., T.C. and W.C.-D.; visualisation, K.K. and C.N.; supervision, C.N., T.C. and W.C.-D.; project administration, K.K.; funding acquisition, K.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data supporting this study are included within the article and/or <xref rid="app1-pharmacy-13-00021" ref-type="app">Supplementary Materials</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>K.K. and T.C. have no conflicts of interest to declare. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. C.N. declares the following conflicts of interest: speaker fees from Janssen, WebMD, Medscape, Merck Pharmaceutical, Tillotts Pharma UK, Lilly and the Pfizer advisory board. W.C.D. declares speaker fees from Dr Falk Pharma and research funding from Bristol Myers Squibb and Crohn&#x02019;s and Colitis UK.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAM</td><td align="left" valign="middle" rowspan="1" colspan="1">Complementary and Alternative Medicines</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CASP</td><td align="left" valign="middle" rowspan="1" colspan="1">Critical Appraisal Skills Programme</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CD</td><td align="left" valign="middle" rowspan="1" colspan="1">Crohn&#x02019;s Disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GP</td><td align="left" valign="middle" rowspan="1" colspan="1">General Practitioner/Family Doctor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HADS</td><td align="left" valign="middle" rowspan="1" colspan="1">Hospital Anxiety and Depression Scale</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCP</td><td align="left" valign="middle" rowspan="1" colspan="1">Healthcare Professionals</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IBD</td><td align="left" valign="middle" rowspan="1" colspan="1">Inflammatory Bowel Disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IBDU</td><td align="left" valign="middle" rowspan="1" colspan="1">Inflammatory Bowel Disease Unclassified</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IUC</td><td align="left" valign="middle" rowspan="1" colspan="1">Indeterminate Ulcerative Colitis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MARS</td><td align="left" valign="middle" rowspan="1" colspan="1">Medication Adherence Report Scale</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MANOVA</td><td align="left" valign="middle" rowspan="1" colspan="1">Multivariate Analysis of Variance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMAS</td><td align="left" valign="middle" rowspan="1" colspan="1">Morisky Medication Adherence Scale</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MPR</td><td align="left" valign="middle" rowspan="1" colspan="1">Medication Possession Ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MVA</td><td align="left" valign="middle" rowspan="1" colspan="1">Multivariable Analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDC</td><td align="left" valign="middle" rowspan="1" colspan="1">Proportion of Days Covered</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QoL</td><td align="left" valign="middle" rowspan="1" colspan="1">Quality of Life</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UC</td><td align="left" valign="middle" rowspan="1" colspan="1">Ulcerative Colitis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UK</td><td align="left" valign="middle" rowspan="1" colspan="1">United Kingdom</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VAS</td><td align="left" valign="middle" rowspan="1" colspan="1">Visual Analogue Scale</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmacy-13-00021"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
</person-group><article-title>Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><fpage>e065186</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2022-065186</pub-id></element-citation></ref><ref id="B2-pharmacy-13-00021"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lachaine</surname><given-names>J.</given-names></name>
<name><surname>Yen</surname><given-names>L.</given-names></name>
<name><surname>Beauchemin</surname><given-names>C.</given-names></name>
<name><surname>Hodgkins</surname><given-names>P.</given-names></name>
</person-group><article-title>Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: Analyses with the RAMQ database</article-title><source>BMC Gastroenterol.</source><year>2013</year><volume>13</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.1186/1471-230X-13-23</pub-id><pub-id pub-id-type="pmid">23363459</pub-id>
</element-citation></ref><ref id="B3-pharmacy-13-00021"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horv&#x000e1;th</surname><given-names>G.</given-names></name>
<name><surname>Farkas</surname><given-names>K.</given-names></name>
<name><surname>Holl&#x000f3;si</surname><given-names>R.</given-names></name>
<name><surname>Nagy</surname><given-names>F.</given-names></name>
<name><surname>Szepes</surname><given-names>Z.</given-names></name>
<name><surname>Papp</surname><given-names>M.</given-names></name>
<name><surname>Palatka</surname><given-names>K.</given-names></name>
<name><surname>Miheller</surname><given-names>P.</given-names></name>
<name><surname>Lakatos</surname><given-names>L.</given-names></name>
<name><surname>Szamosi</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease?</article-title><source>Scand. J. Gastroenterol.</source><year>2012</year><volume>47</volume><fpage>1298</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.3109/00365521.2012.703233</pub-id><pub-id pub-id-type="pmid">22935014</pub-id>
</element-citation></ref><ref id="B4-pharmacy-13-00021"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colombel</surname><given-names>J.-F.</given-names></name>
<name><surname>Panaccione</surname><given-names>R.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.</given-names></name>
<name><surname>Lukas</surname><given-names>M.</given-names></name>
<name><surname>Baert</surname><given-names>F.</given-names></name>
<name><surname>Vanasek</surname><given-names>T.</given-names></name>
<name><surname>Danalioglu</surname><given-names>A.</given-names></name>
<name><surname>Novacek</surname><given-names>G.</given-names></name>
<name><surname>Armuzzi</surname><given-names>A.</given-names></name>
<name><surname>Hebuterne</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Effect of tight control management on Crohn&#x02019;s disease (CALM): A multicentre, randomised, controlled phase 3 trial</article-title><source>Lancet</source><year>2018</year><volume>390</volume><fpage>2779</fpage><lpage>2789</lpage></element-citation></ref><ref id="B5-pharmacy-13-00021"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spekhorst</surname><given-names>L.M.</given-names></name>
<name><surname>Hummel</surname><given-names>T.Z.</given-names></name>
<name><surname>Benninga</surname><given-names>M.A.</given-names></name>
<name><surname>van Rheenen</surname><given-names>P.F.</given-names></name>
<name><surname>Kindermann</surname><given-names>A.</given-names></name>
</person-group><article-title>Adherence to oral maintenance treatment in adolescents with inflammatory bowel disease</article-title><source>J. Pediatr. Gastroenterol. Nutr.</source><year>2016</year><volume>62</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">26230905</pub-id>
</element-citation></ref><ref id="B6-pharmacy-13-00021"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van der Have</surname><given-names>M.</given-names></name>
<name><surname>Oldenburg</surname><given-names>B.</given-names></name>
<name><surname>Kaptein</surname><given-names>A.A.</given-names></name>
<name><surname>Jansen</surname><given-names>J.M.</given-names></name>
<name><surname>Scheffer</surname><given-names>R.C.H.</given-names></name>
<name><surname>van Tuyl</surname><given-names>B.A.</given-names></name>
<name><surname>van der Meulen-de Jong</surname><given-names>A.E.</given-names></name>
<name><surname>Pierik</surname><given-names>M.</given-names></name>
<name><surname>Siersema</surname><given-names>P.D.</given-names></name>
<name><surname>van Oijen</surname><given-names>M.G.H.</given-names></name>
<etal/>
</person-group><article-title>Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: Results from a prospective multicentre study</article-title><source>J. Crohns Colitis</source><year>2016</year><volume>10</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">26738757</pub-id>
</element-citation></ref><ref id="B7-pharmacy-13-00021"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitra</surname><given-names>D.</given-names></name>
<name><surname>Hodgkins</surname><given-names>P.</given-names></name>
<name><surname>Yen</surname><given-names>L.</given-names></name>
<name><surname>Davis</surname><given-names>K.</given-names></name>
<name><surname>Cohen</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis</article-title><source>BMC Gastroenterol.</source><year>2012</year><volume>12</volume><elocation-id>132</elocation-id><pub-id pub-id-type="pmid">23006789</pub-id>
</element-citation></ref><ref id="B8-pharmacy-13-00021"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selinger</surname><given-names>C.P.</given-names></name>
<name><surname>Eaden</surname><given-names>J.</given-names></name>
<name><surname>Jones</surname><given-names>D.B.</given-names></name>
<name><surname>Katelaris</surname><given-names>P.</given-names></name>
<name><surname>Chapman</surname><given-names>G.</given-names></name>
<name><surname>McDonald</surname><given-names>C.</given-names></name>
<name><surname>Smith</surname><given-names>P.</given-names></name>
<name><surname>Lal</surname><given-names>S.</given-names></name>
<name><surname>Leong</surname><given-names>R.W.</given-names></name>
<name><surname>McLaughlin</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2013</year><volume>19</volume><fpage>2199</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1097/MIB.0b013e31829ed8a6</pub-id><pub-id pub-id-type="pmid">23899547</pub-id>
</element-citation></ref><ref id="B9-pharmacy-13-00021"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zand</surname><given-names>A.</given-names></name>
<name><surname>Nguyen</surname><given-names>A.</given-names></name>
<name><surname>Stokes</surname><given-names>Z.</given-names></name>
<name><surname>Van Deen</surname><given-names>W.</given-names></name>
<name><surname>Reynolds</surname><given-names>C.</given-names></name>
<name><surname>Dimitrova</surname><given-names>M.</given-names></name>
<name><surname>Khandadash</surname><given-names>A.</given-names></name>
<name><surname>Dvorsky</surname><given-names>M.</given-names></name>
<name><surname>Sauk</surname><given-names>J.</given-names></name>
<name><surname>Esrailian</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>The development of a screening tool to identify and classify nonadherence in inflammatory bowel disease</article-title><source>Crohn&#x02019;s Colitis 360</source><year>2019</year><volume>1</volume><fpage>otz035</fpage><pub-id pub-id-type="doi">10.1093/crocol/otz035</pub-id></element-citation></ref><ref id="B10-pharmacy-13-00021"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kane</surname><given-names>S.</given-names></name>
<name><surname>Huo</surname><given-names>D.</given-names></name>
<name><surname>Aikens</surname><given-names>J.</given-names></name>
<name><surname>Hanauer</surname><given-names>S.</given-names></name>
</person-group><article-title>Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis</article-title><source>Am. J. Med.</source><year>2003</year><volume>114</volume><fpage>39</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12543288</pub-id>
</element-citation></ref><ref id="B11-pharmacy-13-00021"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eindor-Abarbanel</surname><given-names>A.</given-names></name>
<name><surname>Naftali</surname><given-names>T.</given-names></name>
<name><surname>Ruhimovich</surname><given-names>N.</given-names></name>
<name><surname>Bar-Gil Shitrit</surname><given-names>A.</given-names></name>
<name><surname>Sklerovsky-Benjaminov</surname><given-names>F.</given-names></name>
<name><surname>Konikoff</surname><given-names>F.</given-names></name>
<name><surname>Matalon</surname><given-names>S.</given-names></name>
<name><surname>Shirin</surname><given-names>H.</given-names></name>
<name><surname>Milgrom</surname><given-names>Y.</given-names></name>
<name><surname>Brodie</surname><given-names>E.</given-names></name>
</person-group><article-title>Revealing the puzzle of nonadherence in IBD&#x02014;Assembling the pieces</article-title><source>Inflamm. Bowel Dis.</source><year>2018</year><volume>24</volume><fpage>1352</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1093/ibd/izy013</pub-id><pub-id pub-id-type="pmid">29718228</pub-id>
</element-citation></ref><ref id="B12-pharmacy-13-00021"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>King</surname><given-names>K.</given-names></name>
<name><surname>McGuinness</surname><given-names>S.</given-names></name>
<name><surname>Watson</surname><given-names>N.</given-names></name>
<name><surname>Norton</surname><given-names>C.</given-names></name>
<name><surname>Chalder</surname><given-names>T.</given-names></name>
<name><surname>Czuber-Dochan</surname><given-names>W.</given-names></name>
</person-group><article-title>What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials</article-title><source>Patient Prefer. Adherence</source><year>2023</year><volume>17</volume><fpage>3265</fpage><lpage>3303</lpage><!--<pub-id pub-id-type="pmcid">PMC10725835</pub-id>--><pub-id pub-id-type="doi">10.2147/PPA.S424024</pub-id><pub-id pub-id-type="pmid">38111690</pub-id>
</element-citation></ref><ref id="B13-pharmacy-13-00021"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Unni</surname><given-names>E.</given-names></name>
<name><surname>Bae</surname><given-names>S.</given-names></name>
</person-group><article-title>Exploring a New Theoretical Model to Explain the Behavior of Medication Adherence</article-title><source>Pharmacy</source><year>2022</year><volume>10</volume><elocation-id>43</elocation-id><!--<pub-id pub-id-type="pmcid">PMC9025348</pub-id>--><pub-id pub-id-type="doi">10.3390/pharmacy10020043</pub-id><pub-id pub-id-type="pmid">35448702</pub-id>
</element-citation></ref><ref id="B14-pharmacy-13-00021"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Webb</surname><given-names>T.L.</given-names></name>
<name><surname>Joseph</surname><given-names>J.</given-names></name>
<name><surname>Yardley</surname><given-names>L.</given-names></name>
<name><surname>Michie</surname><given-names>S.</given-names></name>
</person-group><article-title>Using the internet to promote health behavior change: A systematic review and meta-analysis of the impact of theoretical basis, use of behavior change techniques, and mode of delivery on efficacy</article-title><source>J. Med. Internet Res.</source><year>2010</year><volume>12</volume><fpage>e4</fpage><pub-id pub-id-type="doi">10.2196/jmir.1376</pub-id><pub-id pub-id-type="pmid">20164043</pub-id>
</element-citation></ref><ref id="B15-pharmacy-13-00021"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peel</surname><given-names>A.</given-names></name>
<name><surname>Thorpe</surname><given-names>G.</given-names></name>
<name><surname>Deane</surname><given-names>K.</given-names></name>
<name><surname>O&#x02019;Leary</surname><given-names>H.</given-names></name>
</person-group><article-title>Factors associated with non-adherence to oral OBD medication: A systematic review of the literature 1980&#x02013;2013</article-title><source>Gastrointest. Nurs.</source><year>2015</year><volume>13</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.12968/gasn.2015.13.9.17</pub-id></element-citation></ref><ref id="B16-pharmacy-13-00021"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jackson</surname><given-names>C.A.</given-names></name>
<name><surname>Clatworthy</surname><given-names>J.</given-names></name>
<name><surname>Robinson</surname><given-names>A.</given-names></name>
<name><surname>Horne</surname><given-names>R.</given-names></name>
</person-group><article-title>Factors Associated with Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review</article-title><source>Am. J. Gastroenterol.</source><year>2010</year><volume>105</volume><fpage>525</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1038/ajg.2009.685</pub-id><pub-id pub-id-type="pmid">19997092</pub-id>
</element-citation></ref><ref id="B17-pharmacy-13-00021"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vangeli</surname><given-names>E.</given-names></name>
<name><surname>Bakhshi</surname><given-names>S.</given-names></name>
<name><surname>Baker</surname><given-names>A.</given-names></name>
<name><surname>Fisher</surname><given-names>A.</given-names></name>
<name><surname>Bucknor</surname><given-names>D.</given-names></name>
<name><surname>Mrowietz</surname><given-names>U.</given-names></name>
<name><surname>&#x000d6;st&#x000f6;r</surname><given-names>A.J.</given-names></name>
<name><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name>
<name><surname>Lacerda</surname><given-names>A.P.</given-names></name>
<name><surname>Weinman</surname><given-names>J.</given-names></name>
</person-group><article-title>A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases</article-title><source>Adv. Ther.</source><year>2015</year><volume>32</volume><fpage>983</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1007/s12325-015-0256-7</pub-id><pub-id pub-id-type="pmid">26547912</pub-id>
</element-citation></ref><ref id="B18-pharmacy-13-00021"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Page</surname><given-names>M.J.</given-names></name>
<name><surname>McKenzie</surname><given-names>J.E.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.M.</given-names></name>
<name><surname>Boutron</surname><given-names>I.</given-names></name>
<name><surname>Hoffman</surname><given-names>T.C.</given-names></name>
<name><surname>Mulrow</surname><given-names>C.D.</given-names></name>
<name><surname>Shamseer</surname><given-names>L.</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J.M.</given-names></name>
<name><surname>Akl</surname><given-names>E.A.</given-names></name>
<name><surname>Brennan</surname><given-names>S.E.</given-names></name>
<etal/>
</person-group><article-title>The PRISMA 2020 statement: An updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id>
</element-citation></ref><ref id="B19-pharmacy-13-00021"><label>19.</label><element-citation publication-type="webpage"><article-title>Critical Appraisal Skills Programme (CASP) Qualitative Checklist</article-title><comment>Available online: <ext-link xlink:href="https://casp-uk.net/casp-tools-checklists/qualitative-studies-checklist/" ext-link-type="uri">https://casp-uk.net/casp-tools-checklists/qualitative-studies-checklist/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-10-04">(accessed on 4 October 2022)</date-in-citation></element-citation></ref><ref id="B20-pharmacy-13-00021"><label>20.</label><element-citation publication-type="webpage"><article-title>Critical Appraisal Skills Programme (2018). CASP (Cohort Study) Checklist</article-title><comment>Available online: <ext-link xlink:href="https://casp-uk.net/casp-tools-checklists/cohort-study-checklist/" ext-link-type="uri">https://casp-uk.net/casp-tools-checklists/cohort-study-checklist/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-10-04">(accessed on 4 October 2022)</date-in-citation></element-citation></ref><ref id="B21-pharmacy-13-00021"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hodgkins</surname><given-names>P.</given-names></name>
<name><surname>Swinburn</surname><given-names>P.</given-names></name>
<name><surname>Solomon</surname><given-names>D.</given-names></name>
<name><surname>Yen</surname><given-names>L.</given-names></name>
<name><surname>Dewilde</surname><given-names>S.</given-names></name>
<name><surname>Lloyd</surname><given-names>A.</given-names></name>
</person-group><article-title>Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis</article-title><source>Patient Patient-Centered Outcomes Res.</source><year>2012</year><volume>5</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.2165/11595390-000000000-00000</pub-id></element-citation></ref><ref id="B22-pharmacy-13-00021"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gallinger</surname><given-names>Z.R.</given-names></name>
<name><surname>Rumman</surname><given-names>A.</given-names></name>
<name><surname>Nguyen</surname><given-names>G.C.</given-names></name>
</person-group><article-title>Perceptions and attitudes towards medication adherence during pregnancy in inflammatory bowel disease</article-title><source>J. Crohn&#x02019;s Colitis</source><year>2016</year><volume>10</volume><fpage>892</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjw052</pub-id><pub-id pub-id-type="pmid">26896087</pub-id>
</element-citation></ref><ref id="B23-pharmacy-13-00021"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Seow</surname><given-names>C.H.</given-names></name>
<name><surname>Adhikari</surname><given-names>K.</given-names></name>
<name><surname>Metcalfe</surname><given-names>A.</given-names></name>
</person-group><article-title>Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications</article-title><source>Aliment. Pharmacol. Ther.</source><year>2020</year><volume>51</volume><fpage>544</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1111/apt.15596</pub-id><pub-id pub-id-type="pmid">31797416</pub-id>
</element-citation></ref><ref id="B24-pharmacy-13-00021"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>C.</given-names></name>
<name><surname>Nagahori</surname><given-names>M.</given-names></name>
<name><surname>Fujii</surname><given-names>T.</given-names></name>
<name><surname>Yokoyama</surname><given-names>K.</given-names></name>
<name><surname>Yoshimura</surname><given-names>N.</given-names></name>
<name><surname>Kobayashi</surname><given-names>T.</given-names></name>
<name><surname>Yamagami</surname><given-names>H.</given-names></name>
<name><surname>Kitamura</surname><given-names>K.</given-names></name>
<name><surname>Takasji</surname><given-names>K.</given-names></name>
<name><surname>Nakamura</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Non-adherence to medications in pregnant ulcerative colitis patients contributes to disease flares and adverse pregnancy outcomes</article-title><source>Dig. Dis. Sci.</source><year>2021</year><volume>66</volume><fpage>577</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1007/s10620-020-06221-6</pub-id><pub-id pub-id-type="pmid">32249373</pub-id>
</element-citation></ref><ref id="B25-pharmacy-13-00021"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodhand</surname><given-names>J.R.</given-names></name>
<name><surname>Kamperidis</surname><given-names>N.</given-names></name>
<name><surname>Sirwan</surname><given-names>B.</given-names></name>
<name><surname>Macken</surname><given-names>L.</given-names></name>
<name><surname>Tshuma</surname><given-names>N.</given-names></name>
<name><surname>Koodun</surname><given-names>Y.</given-names></name>
<name><surname>Chowdhury</surname><given-names>F.A.</given-names></name>
<name><surname>Croft</surname><given-names>N.M.</given-names></name>
<name><surname>Direkze</surname><given-names>N.</given-names></name>
<name><surname>Langmead</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease</article-title><source>Aliment. Pharmacol. &#x00026;Amp; Ther.</source><year>2013</year><volume>38</volume><fpage>1097</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1111/apt.12476</pub-id></element-citation></ref><ref id="B26-pharmacy-13-00021"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamperidis</surname><given-names>N.</given-names></name>
<name><surname>Goodhand</surname><given-names>J.R.</given-names></name>
<name><surname>Chowdhury</surname><given-names>F.A.</given-names></name>
<name><surname>Koodun</surname><given-names>Y.</given-names></name>
<name><surname>Direzke</surname><given-names>N.C.</given-names></name>
<name><surname>Naik</surname><given-names>S.</given-names></name>
<name><surname>Sanderson</surname><given-names>I.R.</given-names></name>
<name><surname>Croft</surname><given-names>N.M.</given-names></name>
<name><surname>Langmead</surname><given-names>F.L.</given-names></name>
<name><surname>Irving</surname><given-names>P.M.</given-names></name>
<etal/>
</person-group><article-title>Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease</article-title><source>J. Paediatr. Gastroenterol. Nutr.</source><year>2012</year><volume>54</volume><fpage>685</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e3182475e71</pub-id><pub-id pub-id-type="pmid">22197942</pub-id>
</element-citation></ref><ref id="B27-pharmacy-13-00021"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zelante</surname><given-names>A.</given-names></name>
<name><surname>De Giorgi</surname><given-names>A.</given-names></name>
<name><surname>Borgoni</surname><given-names>R.</given-names></name>
<name><surname>Trevisani</surname><given-names>L.</given-names></name>
<name><surname>Gallerani</surname><given-names>M.</given-names></name>
</person-group><article-title>Adherence to medical treatment in inflammatory bowel disease patients</article-title><source>Minerva Gastroenterol. Dietol.</source><year>2014</year><volume>60</volume><fpage>269</fpage><lpage>274</lpage><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/25384805/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/25384805/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="pmid">25384805</pub-id>
</element-citation></ref><ref id="B28-pharmacy-13-00021"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linn</surname><given-names>A.J.</given-names></name>
<name><surname>van Dijk</surname><given-names>L.</given-names></name>
<name><surname>Smit</surname><given-names>E.G.</given-names></name>
<name><surname>Jansen</surname><given-names>J.</given-names></name>
<name><surname>van Weert</surname><given-names>J.C.M.</given-names></name>
</person-group><article-title>May you never forget what is worth remembering: The relation between recall of medical information and medication adherence in patients with inflammatory bowel disease</article-title><source>J. Crohn&#x02019;s Colitis</source><year>2013</year><volume>7</volume><fpage>e543</fpage><lpage>e550</lpage><pub-id pub-id-type="doi">10.1016/j.crohns.2013.04.001</pub-id><pub-id pub-id-type="pmid">23660489</pub-id>
</element-citation></ref><ref id="B29-pharmacy-13-00021"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lasa</surname><given-names>J.</given-names></name>
<name><surname>Correa</surname><given-names>G.</given-names></name>
<name><surname>Fuxman</surname><given-names>C.</given-names></name>
<name><surname>Garbi</surname><given-names>L.</given-names></name>
<name><surname>Linares</surname><given-names>M.E.</given-names></name>
<name><surname>Lubrano</surname><given-names>P.</given-names></name>
<name><surname>Rausch</surname><given-names>A.</given-names></name>
<name><surname>Toro</surname><given-names>M.</given-names></name>
<name><surname>Yantorno</surname><given-names>M.</given-names></name>
<name><surname>Zubiaurre</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Treatment adherence in inflammatory bowel disease patients from Argentina: A multicenter study</article-title><source>Gastroenterol. Res. Pract.</source><year>2020</year><volume>2020</volume><fpage>4060648</fpage><pub-id pub-id-type="doi">10.1155/2020/4060648</pub-id><pub-id pub-id-type="pmid">32411197</pub-id>
</element-citation></ref><ref id="B30-pharmacy-13-00021"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mountifield</surname><given-names>R.</given-names></name>
<name><surname>Andrews</surname><given-names>J.M.</given-names></name>
<name><surname>Mikocka-Walus</surname><given-names>A.</given-names></name>
<name><surname>Bampton</surname><given-names>P.</given-names></name>
</person-group><article-title>Covert dose reduction is a distinct type of medication non-adherence observed across all care settings in inflammatory bowel disease</article-title><source>J. Crohn&#x02019;s Colitis</source><year>2014</year><volume>8</volume><fpage>1723</fpage><lpage>1729</lpage><pub-id pub-id-type="doi">10.1016/j.crohns.2014.08.013</pub-id><pub-id pub-id-type="pmid">25263934</pub-id>
</element-citation></ref><ref id="B31-pharmacy-13-00021"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pittet</surname><given-names>V.</given-names></name>
<name><surname>Rogler</surname><given-names>G.</given-names></name>
<name><surname>Mottet</surname><given-names>C.</given-names></name>
<name><surname>Froehlich</surname><given-names>F.</given-names></name>
<name><surname>Michetti</surname><given-names>P.</given-names></name>
<name><surname>De Saussure Burnand</surname><given-names>B.</given-names></name>
<name><surname>Vader</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Patients&#x02019; information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients</article-title><source>Scand. J. Gastroenterol.</source><year>2014</year><volume>49</volume><fpage>662</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.3109/00365521.2014.896408</pub-id><pub-id pub-id-type="pmid">24617517</pub-id>
</element-citation></ref><ref id="B32-pharmacy-13-00021"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomar</surname><given-names>S.K.</given-names></name>
<name><surname>Kedia</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Upadhyay</surname><given-names>A.D.</given-names></name>
<name><surname>Kamat</surname><given-names>N.</given-names></name>
<name><surname>Bopanna</surname><given-names>S.</given-names></name>
<name><surname>Yadav</surname><given-names>D.P.</given-names></name>
<name><surname>Goyal</surname><given-names>S.</given-names></name>
<name><surname>Jain</surname><given-names>S.</given-names></name>
<name><surname>Makharia</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Higher Education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease</article-title><source>JGH Open</source><year>2019</year><volume>3</volume><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1002/jgh3.12160</pub-id><pub-id pub-id-type="pmid">31406923</pub-id>
</element-citation></ref><ref id="B33-pharmacy-13-00021"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Billioud</surname><given-names>V.</given-names></name>
<name><surname>Laharie</surname><given-names>D.</given-names></name>
<name><surname>Filippi</surname><given-names>J.</given-names></name>
<name><surname>Robin</surname><given-names>X.</given-names></name>
<name><surname>Oussalah</surname><given-names>A.</given-names></name>
<name><surname>Chevaux</surname><given-names>J.P.</given-names></name>
<name><surname>Hebuterne</surname><given-names>X.</given-names></name>
<name><surname>Bigard</surname><given-names>M.A.</given-names></name>
<name><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name>
</person-group><article-title>Adherence to adalimumab therapy in crohn&#x002bc;s disease: A French multicenter experience</article-title><source>Inflamm. Bowel Dis.</source><year>2011</year><volume>17</volume><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1002/ibd.21491</pub-id><pub-id pub-id-type="pmid">21061388</pub-id>
</element-citation></ref><ref id="B34-pharmacy-13-00021"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyle</surname><given-names>M.</given-names></name>
<name><surname>Ting</surname><given-names>A.</given-names></name>
<name><surname>Cury</surname><given-names>D.B.</given-names></name>
<name><surname>Nanda</surname><given-names>K.</given-names></name>
<name><surname>Cheifetz</surname><given-names>A.S.</given-names></name>
<name><surname>Moss</surname><given-names>A.</given-names></name>
</person-group><article-title>Adherence to rectal mesalamine in patients with ulcerative colitis</article-title><source>Inflamm. Bowel Dis.</source><year>2015</year><volume>21</volume><fpage>2873</fpage><lpage>2878</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000562</pub-id><pub-id pub-id-type="pmid">26313693</pub-id>
</element-citation></ref><ref id="B35-pharmacy-13-00021"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000f3;mez-Medina</surname><given-names>C.</given-names></name>
<name><surname>Capilla-Lozano</surname><given-names>M.</given-names></name>
<name><surname>Ballester Ferr&#x000e9;</surname><given-names>M.P.</given-names></name>
<name><surname>Marti- Aguado</surname><given-names>D.</given-names></name>
<name><surname>Crespo</surname><given-names>A.</given-names></name>
<name><surname>Bosca-Watts</surname><given-names>M.M.</given-names></name>
<name><surname>Navarro Cortes</surname><given-names>P.</given-names></name>
<name><surname>Anton</surname><given-names>R.</given-names></name>
<name><surname>Pascual Moreno</surname><given-names>I.</given-names></name>
<name><surname>Tosca Cuquerella</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Thiopurine adherence: High prevalence with low impact in UC Outcomes</article-title><source>Rev. Espa&#x000f1;ola Enfermedades Dig.</source><year>2021</year><volume>114</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.17235/reed.2021.7630/2020</pub-id><pub-id pub-id-type="pmid">33733802</pub-id>
</element-citation></ref><ref id="B36-pharmacy-13-00021"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amiesimaka</surname><given-names>O.A.</given-names></name>
<name><surname>Aluzaite</surname><given-names>K.</given-names></name>
<name><surname>Braund</surname><given-names>R.</given-names></name>
<name><surname>Schultz</surname><given-names>M.</given-names></name>
</person-group><article-title>&#x0201c;It&#x02019;s just like putting your socks on&#x0201d;: Patients&#x02019; perspectives on inflammatory bowel disease medication adherence</article-title><source>Explor. Res. Clin. Soc. Pharm.</source><year>2023</year><volume>12</volume><fpage>100385</fpage><comment>Available online: <ext-link xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11042484/" ext-link-type="uri">https://pmc.ncbi.nlm.nih.gov/articles/PMC11042484/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.1016/j.rcsop.2023.100385</pub-id><pub-id pub-id-type="pmid">38146319</pub-id>
</element-citation></ref><ref id="B37-pharmacy-13-00021"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Devlen</surname><given-names>J.</given-names></name>
<name><surname>Beusterien</surname><given-names>K.</given-names></name>
<name><surname>Yen</surname><given-names>L.</given-names></name>
<name><surname>Ahmed</surname><given-names>A.</given-names></name>
<name><surname>Cheifetz</surname><given-names>A.S.</given-names></name>
<name><surname>Moss</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Barriers to mesalamine adherence in patients with inflammatory bowel disease: A qualitative analysis</article-title><source>J. Manag. Care Pharm.</source><year>2014</year><volume>20</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.18553/jmcp.2014.20.3.309</pub-id></element-citation></ref><ref id="B38-pharmacy-13-00021"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keller</surname><given-names>M.S.</given-names></name>
<name><surname>Mosadeghi</surname><given-names>S.</given-names></name>
<name><surname>Cohen</surname><given-names>E.R.</given-names></name>
<name><surname>Kwan</surname><given-names>J.</given-names></name>
<name><surname>Spiegel</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Reproductive Health and medication concerns for patients with inflammatory bowel disease: Thematic and quantitative analysis using social listening</article-title><source>J. Med. Internet Res.</source><year>2018</year><volume>20</volume><fpage>e206</fpage><pub-id pub-id-type="doi">10.2196/jmir.9870</pub-id><pub-id pub-id-type="pmid">29891471</pub-id>
</element-citation></ref><ref id="B39-pharmacy-13-00021"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balaii</surname><given-names>H.</given-names></name>
<name><surname>Olyanasab Narab</surname><given-names>S.</given-names></name>
<name><surname>Khanabadi</surname><given-names>B.</given-names></name>
<name><surname>Anaraki</surname><given-names>F.A.</given-names></name>
<name><surname>Shahrokh</surname><given-names>S.</given-names></name>
</person-group><article-title>Determining the degree of adherence to treatment in inflammatory bowel disease patients</article-title><source>Gastroenterol. Hepatol. Bed Bench</source><year>2018</year><comment>Available online: <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347981/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347981/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-05">(accessed on 5 March 2023)</date-in-citation></element-citation></ref><ref id="B40-pharmacy-13-00021"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linn</surname><given-names>A.J.</given-names></name>
<name><surname>van Weert</surname><given-names>J.C.</given-names></name>
<name><surname>van Dijk</surname><given-names>L.</given-names></name>
<name><surname>Horne</surname><given-names>R.</given-names></name>
<name><surname>Smit</surname><given-names>E.G.</given-names></name>
</person-group><article-title>The value of nurses&#x02019; tailored communication when discussing medicines: Exploring the relationship between satisfaction, beliefs and adherence</article-title><source>J. Health Psychol.</source><year>2016</year><volume>21</volume><fpage>798</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1177/1359105314539529</pub-id><pub-id pub-id-type="pmid">24997167</pub-id>
</element-citation></ref><ref id="B41-pharmacy-13-00021"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Q.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Zhi</surname><given-names>M.</given-names></name>
<name><surname>Gu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Fan</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Internet and We Chat used by patients with crohn&#x02019;s disease in China: A multi-center questionnaire survey</article-title><source>BMC Gastroenterol.</source><year>2019</year><volume>19</volume><elocation-id>97</elocation-id><pub-id pub-id-type="doi">10.1186/s12876-019-1011-3</pub-id><pub-id pub-id-type="pmid">31221086</pub-id>
</element-citation></ref><ref id="B42-pharmacy-13-00021"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawakami</surname><given-names>A.</given-names></name>
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<name><surname>Naganuma</surname><given-names>M.</given-names></name>
<name><surname>Maeda</surname><given-names>S.</given-names></name>
<name><surname>Kunisaki</surname><given-names>R.</given-names></name>
<name><surname>Yamamoto-Mitani</surname><given-names>N.</given-names></name>
</person-group><article-title>What strategies do ulcerative colitis patients employ to facilitate adherence?</article-title><source>Patient Prefer. Adherence</source><year>2017</year><volume>11</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.2147/PPA.S117841</pub-id><pub-id pub-id-type="pmid">28203059</pub-id>
</element-citation></ref><ref id="B43-pharmacy-13-00021"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keil</surname><given-names>R.</given-names></name>
<name><surname>Wasserbauer</surname><given-names>M.</given-names></name>
<name><surname>Z&#x000e1;dorov&#x000e1;</surname><given-names>Z.</given-names></name>
<name><surname>Kojecky</surname><given-names>V.</given-names></name>
<name><surname>Hlava</surname><given-names>S.</given-names></name>
<name><surname>St&#x02019;ovicek</surname><given-names>J.</given-names></name>
<name><surname>Chudy</surname><given-names>J.</given-names></name>
<name><surname>Roznetinska</surname><given-names>M.</given-names></name>
<name><surname>Drabek</surname><given-names>J.</given-names></name>
<name><surname>Jubisova</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Adherence, risk factors of non-adherence and patient&#x02019;s preferred treatment strategy of Mesalazine in ulcerative colitis: Multicentric Observational Study</article-title><source>Scand. J. Gastroenterol.</source><year>2018</year><volume>53</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1080/00365521.2018.1451915</pub-id><pub-id pub-id-type="pmid">29560753</pub-id>
</element-citation></ref><ref id="B44-pharmacy-13-00021"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawakami</surname><given-names>A.</given-names></name>
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<name><surname>Nishigaki</surname><given-names>M.</given-names></name>
<name><surname>Yoshimura</surname><given-names>N.</given-names></name>
<name><surname>Suzuki</surname><given-names>R.</given-names></name>
<name><surname>Maeda</surname><given-names>S.</given-names></name>
<name><surname>Kunisaki</surname><given-names>R.</given-names></name>
<name><surname>Yamamoto-Mitani</surname><given-names>N.</given-names></name>
</person-group><article-title>A screening instrument to identify ulcerative colitis patients with the high possibility of current non-adherence to aminosalicylate medication based on the health belief model: A cross-sectional study</article-title><source>BMC Gastroenterol.</source><year>2014</year><volume>14</volume><elocation-id>220</elocation-id><pub-id pub-id-type="doi">10.1186/s12876-014-0220-z</pub-id><pub-id pub-id-type="pmid">25523298</pub-id>
</element-citation></ref><ref id="B45-pharmacy-13-00021"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Denesh</surname><given-names>D.</given-names></name>
<name><surname>Carbonell</surname><given-names>J.</given-names></name>
<name><surname>Kane</surname><given-names>J.S.</given-names></name>
<name><surname>Gracie</surname><given-names>D.</given-names></name>
<name><surname>Selinger</surname><given-names>C.P.</given-names></name>
</person-group><article-title>Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of Medicine Administration</article-title><source>Expert Rev. Gastroenterol. Hepatol.</source><year>2021</year><volume>15</volume><fpage>1091</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1080/17474124.2021.1898944</pub-id><pub-id pub-id-type="pmid">33653185</pub-id>
</element-citation></ref><ref id="B46-pharmacy-13-00021"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freitas</surname><given-names>T.H.</given-names></name>
<name><surname>Hyphantis</surname><given-names>T.N.</given-names></name>
<name><surname>Andreoulakis</surname><given-names>E.</given-names></name>
<name><surname>Quevedo</surname><given-names>J.</given-names></name>
<name><surname>Miranda</surname><given-names>H.L.</given-names></name>
<name><surname>Alves</surname><given-names>G.S.</given-names></name>
<name><surname>Souza</surname><given-names>M.H.</given-names></name>
<name><surname>Braga</surname><given-names>L.L.</given-names></name>
<name><surname>Pargament</surname><given-names>K.I.</given-names></name>
<name><surname>Soczynska</surname><given-names>J.K.</given-names></name>
<etal/>
</person-group><article-title>Religious coping and its influence on psychological distress, medication adherence, and quality of life in inflammatory bowel disease</article-title><source>Braz. J. Psychiatry</source><year>2015</year><volume>37</volume><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1590/1516-4446-2014-1507</pub-id><pub-id pub-id-type="pmid">26376052</pub-id>
</element-citation></ref><ref id="B47-pharmacy-13-00021"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawakami</surname><given-names>A.</given-names></name>
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<name><surname>Ochiai</surname><given-names>R.</given-names></name>
<name><surname>Naganuma Makoto Iwao</surname><given-names>Y.</given-names></name>
<name><surname>Hibi</surname><given-names>T.</given-names></name>
<name><surname>Kazuma</surname><given-names>K.</given-names></name>
</person-group><article-title>Difficulties in taking aminosalicylates for patients with ulcerative colitis</article-title><source>Gastroenterol. Nurs.</source><year>2012</year><volume>35</volume><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1097/SGA.0b013e31824033f7</pub-id><pub-id pub-id-type="pmid">22306727</pub-id>
</element-citation></ref><ref id="B48-pharmacy-13-00021"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linn</surname><given-names>A.J.</given-names></name>
<name><surname>van Weert</surname><given-names>J.C.</given-names></name>
<name><surname>Gebeyehu</surname><given-names>B.G.</given-names></name>
<name><surname>Sanders Remco Diviani</surname><given-names>N.</given-names></name>
<name><surname>Smit</surname><given-names>E.G.</given-names></name>
<name><surname>Van Dijk</surname><given-names>L.</given-names></name>
</person-group><article-title>Patients&#x02019; online information-seeking behavior throughout treatment: The impact on medication beliefs and medication adherence</article-title><source>Health Commun.</source><year>2019</year><volume>34</volume><fpage>1461</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1080/10410236.2018.1500430</pub-id><pub-id pub-id-type="pmid">30052088</pub-id>
</element-citation></ref><ref id="B49-pharmacy-13-00021"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moradkhani</surname><given-names>A.</given-names></name>
<name><surname>Kerwin</surname><given-names>L.</given-names></name>
<name><surname>Dudley-Brown</surname><given-names>S.</given-names></name>
<name><surname>Tabibian</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Disease-specific knowledge, coping, and adherence in patients with inflammatory bowel disease</article-title><source>Dig. Dis. Sci.</source><year>2011</year><volume>56</volume><fpage>2972</fpage><lpage>2977</lpage><pub-id pub-id-type="doi">10.1007/s10620-011-1714-y</pub-id><pub-id pub-id-type="pmid">21538016</pub-id>
</element-citation></ref><ref id="B50-pharmacy-13-00021"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>J.Y.</given-names></name>
<name><surname>Shin</surname><given-names>J.E.</given-names></name>
<name><surname>Park</surname><given-names>S.H.</given-names></name>
<name><surname>Park</surname><given-names>D.I.</given-names></name>
<name><surname>Cha</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Disability due to inflammatory bowel disease is correlated with drug compliance, disease activity, and quality of life</article-title><source>Gut Liver</source><year>2017</year><volume>11</volume><fpage>370</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.5009/gnl16422</pub-id><pub-id pub-id-type="pmid">28208008</pub-id>
</element-citation></ref><ref id="B51-pharmacy-13-00021"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bager</surname><given-names>P.</given-names></name>
<name><surname>Julsgaard</surname><given-names>M.</given-names></name>
<name><surname>Vestergaard</surname><given-names>T.</given-names></name>
<name><surname>Christensen</surname><given-names>L.A.</given-names></name>
<name><surname>Dahlerup</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Adherence and quality of care in IBD</article-title><source>Scand. J. Gastroenterol.</source><year>2016</year><volume>51</volume><fpage>1326</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1080/00365521.2016.1195870</pub-id><pub-id pub-id-type="pmid">27311071</pub-id>
</element-citation></ref><ref id="B52-pharmacy-13-00021"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>A.</given-names></name>
<name><surname>Andrews</surname><given-names>J.</given-names></name>
<name><surname>Spizzo</surname><given-names>P.</given-names></name>
<name><surname>Mountifield</surname><given-names>R.</given-names></name>
</person-group><article-title>Medication adherence and complementary therapy usage in inflammatory bowel disease patients during the coronavirus disease 2019 pandemic</article-title><source>JGH Open</source><year>2021</year><volume>5</volume><fpage>585</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1002/jgh3.12537</pub-id><pub-id pub-id-type="pmid">34013059</pub-id>
</element-citation></ref><ref id="B53-pharmacy-13-00021"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Jee</surname><given-names>S.R.</given-names></name>
<name><surname>Kim</surname><given-names>H.W.</given-names></name>
<name><surname>Baek</surname><given-names>D.H.</given-names></name>
<name><surname>Song</surname><given-names>G.A.</given-names></name>
<name><surname>Moon</surname><given-names>W.</given-names></name>
<name><surname>Park</surname><given-names>S.J.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Park</surname><given-names>J.H.</given-names></name>
<etal/>
</person-group><article-title>Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0214129</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0214129</pub-id><pub-id pub-id-type="pmid">30901362</pub-id>
</element-citation></ref><ref id="B54-pharmacy-13-00021"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bruna-Barranco</surname><given-names>I.</given-names></name>
<name><surname>Lu&#x000e9;</surname><given-names>A.</given-names></name>
<name><surname>Gargallo-Puyuelo</surname><given-names>C.J.</given-names></name>
<name><surname>Arroyo</surname><given-names>M.T.</given-names></name>
<name><surname>Alfambra</surname><given-names>E.</given-names></name>
<name><surname>Montero</surname><given-names>J.</given-names></name>
<name><surname>Gomollon</surname><given-names>F.</given-names></name>
</person-group><article-title>Young age and tobacco use are predictors of lower medication adherence in inflammatory bowel disease</article-title><source>Eur. J. Gastroenterol. Hepatol.</source><year>2019</year><volume>31</volume><fpage>948</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000001436</pub-id><pub-id pub-id-type="pmid">31107739</pub-id>
</element-citation></ref><ref id="B55-pharmacy-13-00021"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bucci</surname><given-names>C.</given-names></name>
<name><surname>Zingone</surname><given-names>F.</given-names></name>
<name><surname>Tammaro</surname><given-names>S.</given-names></name>
<name><surname>Iovino</surname><given-names>P.</given-names></name>
<name><surname>Santonicola</surname><given-names>A.</given-names></name>
<name><surname>Ciacci</surname><given-names>C.</given-names></name>
</person-group><article-title>Factors predicting the adherence to the therapy of Italian IBD patients</article-title><source>Gastroenterol. Res. Pract.</source><year>2017</year><volume>2017</volume><fpage>6719345</fpage><pub-id pub-id-type="doi">10.1155/2017/6719345</pub-id><pub-id pub-id-type="pmid">28848602</pub-id>
</element-citation></ref><ref id="B56-pharmacy-13-00021"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.B.</given-names></name>
<name><surname>Kim</surname><given-names>K.O.</given-names></name>
<name><surname>Jang</surname><given-names>B.I.</given-names></name>
<name><surname>Kim</surname><given-names>E.S.</given-names></name>
<name><surname>Cho</surname><given-names>K.B.</given-names></name>
<name><surname>Park</surname><given-names>K.S.</given-names></name>
<name><surname>Chung</surname><given-names>M.K.</given-names></name>
<name><surname>Jeon</surname><given-names>S.W.</given-names></name>
</person-group><article-title>Patients&#x02019; beliefs and attitudes about their treatment for inflammatory bowel disease in Korea</article-title><source>J. Gastroenterol. Hepatol.</source><year>2016</year><volume>31</volume><fpage>575</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1111/jgh.13155</pub-id><pub-id pub-id-type="pmid">26313162</pub-id>
</element-citation></ref><ref id="B57-pharmacy-13-00021"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamp</surname><given-names>K.J.</given-names></name>
<name><surname>Luo</surname><given-names>Z.</given-names></name>
<name><surname>Holmstrom</surname><given-names>A.</given-names></name>
<name><surname>Given</surname><given-names>B.</given-names></name>
<name><surname>Wyatt</surname><given-names>G.</given-names></name>
</person-group><article-title>Self-management through social support among emerging adults with inflammatory bowel disease</article-title><source>Nurs. Res.</source><year>2019</year><volume>68</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1097/NNR.0000000000000354</pub-id><pub-id pub-id-type="pmid">31265438</pub-id>
</element-citation></ref><ref id="B58-pharmacy-13-00021"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Fan</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Hong</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Zhong</surname><given-names>J.</given-names></name>
</person-group><article-title>Applying Machine Learning Models to Predict Medication Nonadherence in Crohn&#x02019;s Disease Maintenance Therapy</article-title><source>Patient Prefer. Adherence</source><year>2020</year><volume>14</volume><fpage>917</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.2147/PPA.S253732</pub-id><pub-id pub-id-type="pmid">32581518</pub-id>
</element-citation></ref><ref id="B59-pharmacy-13-00021"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Can</surname><given-names>G.</given-names></name>
<name><surname>Yozgat</surname><given-names>A.</given-names></name>
<name><surname>Tezel</surname><given-names>A.</given-names></name>
<name><surname>Unsal</surname><given-names>G.</given-names></name>
<name><surname>Soylu</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Beliefs about medicines and adherence to treatment in Turkish patients with inflammatory bowel disease</article-title><source>Turk. J. Gastroenterol.</source><year>2022</year><volume>33</volume><fpage>743</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.5152/tjg.2022.21355</pub-id><pub-id pub-id-type="pmid">35946875</pub-id>
</element-citation></ref><ref id="B60-pharmacy-13-00021"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stone</surname><given-names>J.K.</given-names></name>
<name><surname>Shafer</surname><given-names>L.A.</given-names></name>
<name><surname>Graff</surname><given-names>L.A.</given-names></name>
<name><surname>Lix</surname><given-names>L.</given-names></name>
<name><surname>Witges</surname><given-names>K.</given-names></name>
<name><surname>Targownik</surname><given-names>L.E.</given-names></name>
<name><surname>Haviva</surname><given-names>C.</given-names></name>
<name><surname>Sexton</surname><given-names>K.</given-names></name>
<name><surname>Bernstein</surname><given-names>C.N.</given-names></name>
</person-group><article-title>Utility of the MARS-5 in assessing medication adherence in IBD</article-title><source>Inflamm. Bowel Dis.</source><year>2021</year><volume>27</volume><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1093/ibd/izaa056</pub-id><pub-id pub-id-type="pmid">32195533</pub-id>
</element-citation></ref><ref id="B61-pharmacy-13-00021"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrade</surname><given-names>L.D.</given-names></name>
<name><surname>Oliveira</surname><given-names>F.A.</given-names></name>
<name><surname>Mariano</surname><given-names>V.D.</given-names></name>
<name><surname>Santos</surname><given-names>M.C.</given-names></name>
<name><surname>Pereira</surname><given-names>F.A.</given-names></name>
<name><surname>Dos Santos</surname><given-names>C.I.</given-names></name>
<name><surname>Fortes</surname><given-names>F.M.</given-names></name>
<name><surname>Primentel</surname><given-names>A.M.</given-names></name>
<name><surname>Mota</surname><given-names>J.A.</given-names></name>
<name><surname>Almeida</surname><given-names>N.P.</given-names></name>
<etal/>
</person-group><article-title>Adherence to medical treatment in inflammatory bowel disease patients from a referral center in Bahia-Brazil</article-title><source>BioMed Res. Int.</source><year>2020</year><volume>2020</volume><elocation-id>5269493</elocation-id><pub-id pub-id-type="doi">10.1155/2020/5269493</pub-id><pub-id pub-id-type="pmid">33029512</pub-id>
</element-citation></ref><ref id="B62-pharmacy-13-00021"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calvo Arbeloa</surname><given-names>M.</given-names></name>
<name><surname>Arrondo Velasco</surname><given-names>A.</given-names></name>
<name><surname>Rodriguez Esquiroz</surname><given-names>A.</given-names></name>
<name><surname>Pola Garcia</surname><given-names>J.</given-names></name>
<name><surname>Pinilla Lebrero</surname><given-names>G.</given-names></name>
<name><surname>Tejada Marin</surname><given-names>D.</given-names></name>
<name><surname>Elizondo Armendariz</surname><given-names>J.</given-names></name>
<name><surname>Sarobe Carricas</surname><given-names>M.</given-names></name>
</person-group><article-title>Adherence to adalimumab, golimumab and ustekinumab therapy in inflammatory bowel disease</article-title><source>Farm. Hosp.</source><year>2020</year><volume>44</volume><fpage>62</fpage><lpage>67</lpage><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/32452317/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/32452317/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="pmid">32452317</pub-id>
</element-citation></ref><ref id="B63-pharmacy-13-00021"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>G.C.</given-names></name>
<name><surname>Croitoru</surname><given-names>K.</given-names></name>
<name><surname>Silverberg</surname><given-names>M.S.</given-names></name>
<name><surname>Steinhart</surname><given-names>A.H.</given-names></name>
<name><surname>Weizman</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Use of complementary and alternative medicine for inflammatory bowel disease is associated with worse adherence to conventional therapy</article-title><source>Inflamm. Bowel Dis.</source><year>2016</year><volume>22</volume><fpage>1412</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000773</pub-id><pub-id pub-id-type="pmid">27120570</pub-id>
</element-citation></ref><ref id="B64-pharmacy-13-00021"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ozturk</surname><given-names>N.</given-names></name>
<name><surname>Yidirim</surname><given-names>Y.</given-names></name>
</person-group><article-title>Drug Compliance and Quality of Life in Individuals with Inflammatory Bowel Disease: A Descriptive and Cross-Sectional Study</article-title><source>Int. J. Caring Sci.</source><year>2023</year><volume>16</volume><fpage>474</fpage><lpage>487</lpage></element-citation></ref><ref id="B65-pharmacy-13-00021"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tae</surname><given-names>C.H.</given-names></name>
<name><surname>Jung</surname><given-names>S.A.</given-names></name>
<name><surname>Moon</surname><given-names>H.S.</given-names></name>
<name><surname>Seo</surname><given-names>J.A.</given-names></name>
<name><surname>Song</surname><given-names>H.K.</given-names></name>
<name><surname>Moon</surname><given-names>C.M.</given-names></name>
<name><surname>Kim</surname><given-names>S.-E.</given-names></name>
<name><surname>Shim</surname><given-names>K.-N.</given-names></name>
<name><surname>Jung</surname><given-names>H.-K.</given-names></name>
</person-group><article-title>Importance of patients&#x02019; knowledge of their prescribed medication in improving treatment adherence in inflammatory bowel disease</article-title><source>J. Clin. Gastroenterol.</source><year>2016</year><volume>50</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1097/MCG.0000000000000431</pub-id><pub-id pub-id-type="pmid">26501880</pub-id>
</element-citation></ref><ref id="B66-pharmacy-13-00021"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banerjee</surname><given-names>R.</given-names></name>
<name><surname>Pal</surname><given-names>P.</given-names></name>
<name><surname>Adigopula</surname><given-names>B.</given-names></name>
<name><surname>Reddy</surname><given-names>D.N.</given-names></name>
</person-group><article-title>Impact of demographic, clinical and psychosocial variables on drug adherence and outcomes in Indian patients with inflammatory bowel disease</article-title><source>J. Clin. Gastroenterol.</source><year>2021</year><volume>55</volume><fpage>e92</fpage><lpage>e99</lpage><pub-id pub-id-type="doi">10.1097/MCG.0000000000001480</pub-id><pub-id pub-id-type="pmid">33405436</pub-id>
</element-citation></ref><ref id="B67-pharmacy-13-00021"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campos</surname><given-names>S.</given-names></name>
<name><surname>Portela</surname><given-names>F.</given-names></name>
<name><surname>Sousa</surname><given-names>P.</given-names></name>
<name><surname>Sofia</surname><given-names>C.</given-names></name>
</person-group><article-title>Inflammatory bowel disease: Adherence to immunomodulators in a biological therapy era</article-title><source>Eur. J. Gastroenterol. Hepatol.</source><year>2016</year><volume>28</volume><fpage>1313</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000000704</pub-id><pub-id pub-id-type="pmid">27501126</pub-id>
</element-citation></ref><ref id="B68-pharmacy-13-00021"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franco</surname><given-names>F.C.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.C.</given-names></name>
<name><surname>Gaburri</surname><given-names>P.D.</given-names></name>
<name><surname>Franco</surname><given-names>D.C.</given-names></name>
<name><surname>Chebli</surname><given-names>J.M.</given-names></name>
</person-group><article-title>High prevalence of non-adherence to ulcerative colitis therapy in remission: Knowing the problem to prevent loss</article-title><source>Arq. Gastroenterol.</source><year>2022</year><volume>59</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1590/s0004-2803.202200001-08</pub-id><pub-id pub-id-type="pmid">35442335</pub-id>
</element-citation></ref><ref id="B69-pharmacy-13-00021"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moss</surname><given-names>A.C.</given-names></name>
<name><surname>Lillis</surname><given-names>Y.</given-names></name>
<name><surname>Edwards George</surname><given-names>J.B.</given-names></name>
<name><surname>Choudhry</surname><given-names>N.K.</given-names></name>
<name><surname>Berg</surname><given-names>A.H.</given-names></name>
<name><surname>Cheifetz</surname><given-names>A.S.</given-names></name>
<name><surname>Horowitz</surname><given-names>G.</given-names></name>
<name><surname>Leffler</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Attitudes to mesalamine questionnaire: A novel tool to predict mesalamine nonadherence in patients with IBD</article-title><source>Am. J. Gastroenterol.</source><year>2014</year><volume>109</volume><fpage>1850</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.158</pub-id><pub-id pub-id-type="pmid">24913040</pub-id>
</element-citation></ref><ref id="B70-pharmacy-13-00021"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coenen</surname><given-names>S.</given-names></name>
<name><surname>Weyts</surname><given-names>E.</given-names></name>
<name><surname>Ballet</surname><given-names>V.</given-names></name>
<name><surname>Ballet</surname><given-names>V.</given-names></name>
<name><surname>Noman</surname><given-names>M.</given-names></name>
<name><surname>Van Assche</surname><given-names>G.</given-names></name>
<name><surname>Vermeire</surname><given-names>S.</given-names></name>
<name><surname>Van Emelen</surname><given-names>J.</given-names></name>
<name><surname>Ferrante</surname><given-names>M.</given-names></name>
</person-group><article-title>Identifying predictors of low adherence in patients with inflammatory bowel disease</article-title><source>Eur. J. Gastroenterol. Hepatol.</source><year>2016</year><volume>28</volume><fpage>503</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000000570</pub-id><pub-id pub-id-type="pmid">26760588</pub-id>
</element-citation></ref><ref id="B71-pharmacy-13-00021"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Castro</surname><given-names>M.L.</given-names></name>
<name><surname>Sanrom&#x000e1;n</surname><given-names>L.</given-names></name>
<name><surname>Mart&#x000ed;n</surname><given-names>A.</given-names></name>
<name><surname>Figueira</surname><given-names>M.</given-names></name>
<name><surname>Martinez</surname><given-names>N.</given-names></name>
<name><surname>Hernandez</surname><given-names>V.</given-names></name>
<name><surname>Del Campo</surname><given-names>V.</given-names></name>
<name><surname>Pineda</surname><given-names>J.R.</given-names></name>
<name><surname>Martinez-Cadilla</surname><given-names>J.</given-names></name>
<name><surname>Pereira</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index</article-title><source>Rev. Espa&#x000f1;ola Enfermedades Dig.</source><year>2017</year><volume>109</volume><fpage>542</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.17235/reed.2017.5137/2017</pub-id></element-citation></ref><ref id="B72-pharmacy-13-00021"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dasarathy</surname><given-names>S.S.</given-names></name>
<name><surname>Long</surname><given-names>M.D.</given-names></name>
<name><surname>Lackner</surname><given-names>J.M.</given-names></name>
<name><surname>Ben-Ami Shor</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Bar</surname><given-names>N.</given-names></name>
<name><surname>Ha</surname><given-names>C.</given-names></name>
<name><surname>Weiss</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Psychological factors associated with adherence to oral treatment in ulcerative colitis</article-title><source>Inflamm. Bowel Dis.</source><year>2023</year><volume>29</volume><fpage>97</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1093/ibd/izac051</pub-id><pub-id pub-id-type="pmid">35325148</pub-id>
</element-citation></ref><ref id="B73-pharmacy-13-00021"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nahon</surname><given-names>S.</given-names></name>
<name><surname>Lahmek</surname><given-names>P.</given-names></name>
<name><surname>Saas</surname><given-names>C.</given-names></name>
<name><surname>Durance</surname><given-names>C.</given-names></name>
<name><surname>Olympie</surname><given-names>A.</given-names></name>
<name><surname>Lesgourgures</surname><given-names>B.</given-names></name>
<name><surname>Gendre</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients</article-title><source>Inflamm. Bowel Dis.</source><year>2011</year><volume>17</volume><fpage>1270</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1002/ibd.21482</pub-id><pub-id pub-id-type="pmid">21560190</pub-id>
</element-citation></ref><ref id="B74-pharmacy-13-00021"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Severs</surname><given-names>M.</given-names></name>
<name><surname>Mangen</surname><given-names>M.J.</given-names></name>
<name><surname>Fidder</surname><given-names>H.H.</given-names></name>
<name><surname>van der Valk</surname><given-names>M.E.</given-names></name>
<name><surname>van der Have</surname><given-names>M.</given-names></name>
<name><surname>van Bodegraven</surname><given-names>A.A.</given-names></name>
<name><surname>Clemens</surname><given-names>C.H.M.</given-names></name>
<name><surname>Dijkstra</surname><given-names>G.</given-names></name>
<name><surname>Jansen</surname><given-names>J.M.</given-names></name>
<name><surname>de Jong</surname><given-names>D.J.</given-names></name>
<etal/>
</person-group><article-title>Clinical predictors of future nonadherence in inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2017</year><volume>23</volume><fpage>1568</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000001201</pub-id><pub-id pub-id-type="pmid">28700534</pub-id>
</element-citation></ref><ref id="B75-pharmacy-13-00021"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Engel</surname><given-names>T.</given-names></name>
<name><surname>Ungar</surname><given-names>B.</given-names></name>
<name><surname>Ben-Haim</surname><given-names>G.</given-names></name>
<name><surname>Levhar</surname><given-names>N.</given-names></name>
<name><surname>Eliakim</surname><given-names>R.</given-names></name>
<name><surname>Ben-Horin</surname><given-names>S.</given-names></name>
</person-group><article-title>Re-phrasing the question: A simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease</article-title><source>United Eur. Gastroenterol. J.</source><year>2017</year><volume>5</volume><fpage>880</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1177/2050640616687838</pub-id></element-citation></ref><ref id="B76-pharmacy-13-00021"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghadir</surname><given-names>M.R.</given-names></name>
<name><surname>Bagheri</surname><given-names>M.</given-names></name>
<name><surname>Vahedi</surname><given-names>H.</given-names></name>
<name><surname>Daryani</surname><given-names>N.E.</given-names></name>
<name><surname>Malekzadeh</surname><given-names>R.</given-names></name>
<name><surname>Hormati</surname><given-names>A.</given-names></name>
<name><surname>Kolahdoozan</surname><given-names>S.</given-names></name>
<name><surname>Chaharmahali</surname><given-names>M.</given-names></name>
</person-group><article-title>Nonadherence to Medication in Inflammatory Bowel Disease: Rate and Reasons</article-title><source>Middle East J. Dig. Dis.</source><year>2016</year><volume>8</volume><fpage>116</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.15171/mejdd.2016.16</pub-id><pub-id pub-id-type="pmid">27252818</pub-id>
</element-citation></ref><ref id="B77-pharmacy-13-00021"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iborra</surname><given-names>I.</given-names></name>
<name><surname>Puig</surname><given-names>M.</given-names></name>
<name><surname>Mar&#x000ed;n</surname><given-names>L.</given-names></name>
<name><surname>Calafat</surname><given-names>M.</given-names></name>
<name><surname>Canete</surname><given-names>F.</given-names></name>
<name><surname>Quinones</surname><given-names>C.</given-names></name>
<name><surname>Gonzalez-Gonzalez</surname><given-names>L.</given-names></name>
<name><surname>Cardona</surname><given-names>G.</given-names></name>
<name><surname>Manosa</surname><given-names>M.</given-names></name>
<name><surname>Domenech</surname><given-names>E.</given-names></name>
</person-group><article-title>Treatment adherence and clinical outcomes of patients with inflammatory bowel disease on biological agents during the SARS-COV-2 pandemic</article-title><source>Dig. Dis. Sci.</source><year>2021</year><volume>66</volume><fpage>4191</fpage><lpage>4196</lpage><pub-id pub-id-type="doi">10.1007/s10620-020-06807-0</pub-id><pub-id pub-id-type="pmid">33469807</pub-id>
</element-citation></ref><ref id="B78-pharmacy-13-00021"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magalh&#x000e3;es</surname><given-names>J.</given-names></name>
<name><surname>Dias</surname><given-names>F.</given-names></name>
<name><surname>Boal Carvalho</surname><given-names>P.</given-names></name>
<name><surname>Leite</surname><given-names>S.</given-names></name>
<name><surname>Moreira</surname><given-names>M.J.</given-names></name>
<name><surname>Cotter</surname><given-names>J.</given-names></name>
</person-group><article-title>Treatment of inflammatory bowel disease: Is your patient at risk of Non-Adherence?</article-title><source>Acta M&#x000e9;dica Port.</source><year>2014</year><volume>27</volume><fpage>576</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.20344/amp.5090</pub-id></element-citation></ref><ref id="B79-pharmacy-13-00021"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>K.</given-names></name>
<name><surname>Fujii</surname><given-names>H.</given-names></name>
<name><surname>Yamauchi</surname><given-names>T.</given-names></name>
<name><surname>Kato-Hayashi</surname><given-names>H.</given-names></name>
<name><surname>Ishihara</surname><given-names>M.</given-names></name>
<name><surname>Lihara</surname><given-names>H.</given-names></name>
<name><surname>Hirose</surname><given-names>C.</given-names></name>
<name><surname>Nishida</surname><given-names>S.</given-names></name>
<name><surname>Funato</surname><given-names>M.</given-names></name>
<name><surname>Kobayashi</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Questionnaire survey to identify meal habits which influence adherence to oral 5-aminosalicylic acid regimens in patients with ulcerative colitis</article-title><source>J. Pharm. Pract. Res.</source><year>2021</year><volume>51</volume><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1002/jppr.1712</pub-id></element-citation></ref><ref id="B80-pharmacy-13-00021"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kato</surname><given-names>S.</given-names></name>
<name><surname>Kani</surname><given-names>K.</given-names></name>
<name><surname>Kobayashi</surname><given-names>T.</given-names></name>
<name><surname>Yamamoto</surname><given-names>R.</given-names></name>
<name><surname>Nagoshi</surname><given-names>S.</given-names></name>
<name><surname>Yakabi</surname><given-names>K.</given-names></name>
</person-group><article-title>Adherence to oral 5-aminosalicylic acid by patients with quiescent ulcerative colitis: A questionnaire survey</article-title><source>Nihon Shokakibyo Gakkai Zasshi</source><year>2015</year><volume>112</volume><fpage>1819</fpage><lpage>1829</lpage><pub-id pub-id-type="pmid">26440684</pub-id>
</element-citation></ref><ref id="B81-pharmacy-13-00021"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>J.K.</given-names></name>
<name><surname>Lee</surname><given-names>Y.J.</given-names></name>
<name><surname>Park</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Medication-related knowledge and medication adherence in paediatric and adolescent patients with inflammatory bowel disease</article-title><source>J. Korean Med. Sci.</source><year>2020</year><volume>35</volume><fpage>e92</fpage><pub-id pub-id-type="doi">10.3346/jkms.2020.35.e92</pub-id><pub-id pub-id-type="pmid">32281312</pub-id>
</element-citation></ref><ref id="B82-pharmacy-13-00021"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gillespie</surname><given-names>D.</given-names></name>
<name><surname>Hood</surname><given-names>K.</given-names></name>
<name><surname>Farewell</surname><given-names>D.</given-names></name>
<name><surname>Stenson</surname><given-names>R.</given-names></name>
<name><surname>Probert</surname><given-names>C.</given-names></name>
<name><surname>Hawthorne</surname><given-names>A.B.</given-names></name>
</person-group><article-title>Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis</article-title><source>Inflamm. Bowel Dis.</source><year>2014</year><volume>20</volume><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1097/01.MIB.0000437500.60546.2a</pub-id><pub-id pub-id-type="pmid">24284414</pub-id>
</element-citation></ref><ref id="B83-pharmacy-13-00021"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribaldone</surname><given-names>D.G.</given-names></name>
<name><surname>Vernero</surname><given-names>M.</given-names></name>
<name><surname>Saracco</surname><given-names>G.M.</given-names></name>
<name><surname>Pellicano</surname><given-names>R.</given-names></name>
<name><surname>Finocchiaro</surname><given-names>F.</given-names></name>
<name><surname>Caviglia</surname><given-names>G.P.</given-names></name>
<name><surname>Astegiano</surname><given-names>M.</given-names></name>
</person-group><article-title>The adherence to the therapy in inflammatory bowel disease: Beyond the number of the tablets</article-title><source>Scand. J. Gastroenterol.</source><year>2017</year><volume>53</volume><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1080/00365521.2017.1405070</pub-id><pub-id pub-id-type="pmid">29228844</pub-id>
</element-citation></ref><ref id="B84-pharmacy-13-00021"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ballester</surname><given-names>M.P.</given-names></name>
<name><surname>Marti-Aguado</surname><given-names>D.</given-names></name>
<name><surname>Fullana</surname><given-names>M.</given-names></name>
<name><surname>Bosca-Watts</surname><given-names>M.M.</given-names></name>
<name><surname>Tosca</surname><given-names>J.</given-names></name>
<name><surname>Romero</surname><given-names>E.</given-names></name>
<name><surname>Sanchez</surname><given-names>A.</given-names></name>
<name><surname>Navarro-Cortes</surname><given-names>P.</given-names></name>
<name><surname>Anton</surname><given-names>R.</given-names></name>
<name><surname>Mora</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an Electronic Management System</article-title><source>Int. J. Color. Dis.</source><year>2019</year><volume>34</volume><fpage>1053</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1007/s00384-019-03271-9</pub-id></element-citation></ref><ref id="B85-pharmacy-13-00021"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gatapoulou</surname><given-names>A.</given-names></name>
<name><surname>Christodoulou</surname><given-names>D.K.</given-names></name>
<name><surname>Katsanos</surname><given-names>K.H.</given-names></name>
<name><surname>Bakos</surname><given-names>D.</given-names></name>
<name><surname>Mouzas</surname><given-names>I.</given-names></name>
<name><surname>Tzouvala</surname><given-names>M.</given-names></name>
<name><surname>Theodoropoulou</surname><given-names>A.</given-names></name>
<name><surname>Paspatis</surname><given-names>G.</given-names></name>
<name><surname>Theocharis</surname><given-names>G.</given-names></name>
<name><surname>Thomopoulos</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: A real-world multicenter, noninterventional, Observational Study in Greece</article-title><source>Eur. J. Gastroenterol. Hepatol.</source><year>2021</year><volume>33</volume><fpage>e615</fpage><lpage>e624</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000002182</pub-id><pub-id pub-id-type="pmid">34034278</pub-id>
</element-citation></ref><ref id="B86-pharmacy-13-00021"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Govani</surname><given-names>S.M.</given-names></name>
<name><surname>Noureldin</surname><given-names>M.</given-names></name>
<name><surname>Higgins</surname><given-names>P.D.</given-names></name>
<name><surname>Heisler</surname><given-names>M.</given-names></name>
<name><surname>Saini</surname><given-names>S.D.</given-names></name>
<name><surname>Stidham</surname><given-names>R.W.</given-names></name>
<name><surname>Waljee</surname><given-names>J.F.</given-names></name>
<name><surname>Waljee</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Defining an optimal adherence threshold for patients taking subcutaneous anti-tnfs for inflammatory bowel diseases</article-title><source>Am. J. Gastroenterol.</source><year>2018</year><volume>113</volume><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1038/ajg.2017.438</pub-id><pub-id pub-id-type="pmid">29231192</pub-id>
</element-citation></ref><ref id="B87-pharmacy-13-00021"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramos</surname><given-names>L.</given-names></name>
<name><surname>Ramos-Rodr&#x000ed;guez</surname><given-names>J.</given-names></name>
<name><surname>Barreda</surname><given-names>R.D.</given-names></name>
<name><surname>Gutierrez-Nicolas</surname><given-names>F.</given-names></name>
<name><surname>Carrilo-Palau</surname><given-names>M.</given-names></name>
<name><surname>Alonso-Abreu</surname><given-names>I.</given-names></name>
<name><surname>Nazco-Casariego</surname><given-names>J.</given-names></name>
<name><surname>Enrique</surname><given-names>Q.</given-names></name>
</person-group><article-title>Adherence to subcutaneous biologic treatment for inflammatory bowel disease</article-title><source>Gastroenterol. Hepatol.</source><year>2022</year><volume>45</volume><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.gastrohep.2021.04.011</pub-id><pub-id pub-id-type="pmid">34051312</pub-id>
</element-citation></ref><ref id="B88-pharmacy-13-00021"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wentworth</surname><given-names>B.J.</given-names></name>
<name><surname>Buerlein</surname><given-names>R.C.</given-names></name>
<name><surname>Tuskey</surname><given-names>A.G.</given-names></name>
<name><surname>Overby</surname><given-names>M.A.</given-names></name>
<name><surname>Smolkin</surname><given-names>M.E.</given-names></name>
<name><surname>Behm</surname><given-names>B.W.</given-names></name>
</person-group><article-title>Nonadherence to biologic therapies in inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2018</year><volume>24</volume><fpage>2053</fpage><lpage>2061</lpage><pub-id pub-id-type="doi">10.1093/ibd/izy102</pub-id><pub-id pub-id-type="pmid">29668917</pub-id>
</element-citation></ref><ref id="B89-pharmacy-13-00021"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>N.B.</given-names></name>
<name><surname>Haydek</surname><given-names>J.</given-names></name>
<name><surname>Slaughter</surname><given-names>J.</given-names></name>
<name><surname>Ashton</surname><given-names>J.R.</given-names></name>
<name><surname>Zuckerman</surname><given-names>A.D.</given-names></name>
<name><surname>Wong</surname><given-names>R.</given-names></name>
<name><surname>Raffa</surname><given-names>F.</given-names></name>
<name><surname>Garrett</surname><given-names>A.</given-names></name>
<name><surname>Duley</surname><given-names>C.</given-names></name>
<name><surname>Annis</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Risk factors for medication nonadherence to self-injectable biologic therapy in adult patients with inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2020</year><volume>26</volume><fpage>314</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1093/ibd/izz253</pub-id><pub-id pub-id-type="pmid">31671188</pub-id>
</element-citation></ref><ref id="B90-pharmacy-13-00021"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yen</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Hodgkins</surname><given-names>P.</given-names></name>
<name><surname>Cohen</surname><given-names>R.D.</given-names></name>
<name><surname>Nichol</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy</article-title><source>J. Manag. Care Pharm.</source><year>2012</year><volume>18</volume><fpage>701</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.18553/jmcp.2012.18.9.701</pub-id><pub-id pub-id-type="pmid">23206213</pub-id>
</element-citation></ref><ref id="B91-pharmacy-13-00021"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhasin</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>H.</given-names></name>
<name><surname>Targownik</surname><given-names>L.E.</given-names></name>
<name><surname>Israeli</surname><given-names>E.</given-names></name>
<name><surname>Bernstein</surname><given-names>C.N.</given-names></name>
</person-group><article-title>Rates and reasons for nonuse of prescription medication for inflammatory bowel disease in a referral clinic</article-title><source>Inflamm. Bowel Dis.</source><year>2016</year><volume>22</volume><fpage>919</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000753</pub-id><pub-id pub-id-type="pmid">26933748</pub-id>
</element-citation></ref><ref id="B92-pharmacy-13-00021"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calloway</surname><given-names>A.</given-names></name>
<name><surname>Dalal</surname><given-names>R.</given-names></name>
<name><surname>Beaulieu</surname><given-names>D.B.</given-names></name>
<name><surname>Duley</surname><given-names>C.</given-names></name>
<name><surname>Annis</surname><given-names>K.</given-names></name>
<name><surname>Gaines</surname><given-names>L.</given-names></name>
<name><surname>Slaughter</surname><given-names>C.</given-names></name>
<name><surname>Schwartz</surname><given-names>D.A.</given-names></name>
<name><surname>Horst</surname><given-names>S.</given-names></name>
</person-group><article-title>Depressive symptoms predict anti-tumor necrosis factor therapy noncompliance in patients with inflammatory bowel disease</article-title><source>Dig. Dis. Sci.</source><year>2017</year><volume>62</volume><fpage>3563</fpage><lpage>3567</lpage><pub-id pub-id-type="doi">10.1007/s10620-017-4800-y</pub-id><pub-id pub-id-type="pmid">29052816</pub-id>
</element-citation></ref><ref id="B93-pharmacy-13-00021"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martelli</surname><given-names>L.</given-names></name>
<name><surname>Lopez</surname><given-names>A.</given-names></name>
<name><surname>Strobel</surname><given-names>S.</given-names></name>
<name><surname>Danese Silvio Roblin</surname><given-names>X.</given-names></name>
<name><surname>Baumann</surname><given-names>C.</given-names></name>
<name><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name>
</person-group><article-title>Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting</article-title><source>J. Dig. Dis.</source><year>2017</year><volume>18</volume><fpage>566</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1111/1751-2980.12539</pub-id><pub-id pub-id-type="pmid">28858439</pub-id>
</element-citation></ref><ref id="B94-pharmacy-13-00021"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>K.L.</given-names></name>
<name><surname>Quan</surname><given-names>H.</given-names></name>
<name><surname>Rabi</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Measuring medication adherence in patients with incident hypertension: A retrospective cohort study</article-title><source>BMC Health Serv. Res.</source><year>2017</year><volume>17</volume><elocation-id>135</elocation-id><pub-id pub-id-type="doi">10.1186/s12913-017-2073-y</pub-id><pub-id pub-id-type="pmid">28193217</pub-id>
</element-citation></ref><ref id="B95-pharmacy-13-00021"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Tiao</surname><given-names>D.</given-names></name>
<name><surname>Selinger</surname><given-names>C.</given-names></name>
<name><surname>Leong</surname><given-names>R.</given-names></name>
</person-group><article-title>Medication adherence in inflammatory bowel disease</article-title><source>Intest. Res.</source><year>2017</year><volume>15</volume><fpage>434</fpage><pub-id pub-id-type="doi">10.5217/ir.2017.15.4.434</pub-id><pub-id pub-id-type="pmid">29142511</pub-id>
</element-citation></ref><ref id="B96-pharmacy-13-00021"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDermott</surname><given-names>E.</given-names></name>
<name><surname>Healy</surname><given-names>G.</given-names></name>
<name><surname>Mullen</surname><given-names>G.</given-names></name>
<name><surname>Keegan</surname><given-names>D.</given-names></name>
<name><surname>Byrne</surname><given-names>K.</given-names></name>
<name><surname>Guerandel</surname><given-names>A.</given-names></name>
<name><surname>Forry</surname><given-names>M.</given-names></name>
<name><surname>Moloney</surname><given-names>J.</given-names></name>
<name><surname>Doherty</surname><given-names>G.</given-names></name>
<name><surname>Cullen</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Patient education in inflammatory bowel disease: A patient-centred, mixed methodology study</article-title><source>J. Crohns Colitis</source><year>2018</year><volume>12</volume><fpage>419</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjx175</pub-id><pub-id pub-id-type="pmid">29293956</pub-id>
</element-citation></ref><ref id="B97-pharmacy-13-00021"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>King</surname><given-names>K.</given-names></name>
<name><surname>Horne</surname><given-names>R.</given-names></name>
<name><surname>Cooper</surname><given-names>V.</given-names></name>
<name><surname>Glendinning</surname><given-names>E.</given-names></name>
<name><surname>Michie</surname><given-names>S.</given-names></name>
<name><surname>Chalder</surname><given-names>T.</given-names></name>
<collab>SUPA Group</collab>
</person-group><article-title>The development of an intervention to support uptake and adherence to antiretroviral therapy in people living with HIV: The SUPA intervention. A brief report</article-title><source>Transl. Behav. Med.</source><year>2022</year><volume>12</volume><fpage>ibab104</fpage><pub-id pub-id-type="doi">10.1093/tbm/ibab104</pub-id><pub-id pub-id-type="pmid">34379122</pub-id>
</element-citation></ref><ref id="B98-pharmacy-13-00021"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bokemeyer</surname><given-names>B.</given-names></name>
<name><surname>Teml</surname><given-names>A.</given-names></name>
<name><surname>Roggel</surname><given-names>C.</given-names></name>
<name><surname>Hartmann</surname><given-names>P.</given-names></name>
<name><surname>Fischer</surname><given-names>C.</given-names></name>
<name><surname>Schaeffeler</surname><given-names>E.</given-names></name>
<name><surname>Schwab</surname><given-names>M.</given-names></name>
</person-group><article-title>Adherence to thiopurine treatment in out-patients with Crohn&#x02019;s disease</article-title><source>Aliment. Pharmacol. Ther.</source><year>2007</year><volume>26</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2007.03365.x</pub-id><pub-id pub-id-type="pmid">17593067</pub-id>
</element-citation></ref><ref id="B99-pharmacy-13-00021"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Te Poel</surname><given-names>F.</given-names></name>
<name><surname>Baumgartner</surname><given-names>S.E.</given-names></name>
<name><surname>Hartmann</surname><given-names>T.</given-names></name>
<name><surname>Tanis</surname><given-names>M.</given-names></name>
</person-group><article-title>The curious case of cyberchondria: A longitudinal study on the reciprocal relationship between health anxiety and online health information seeking</article-title><source>J. Anxiety Disord.</source><year>2016</year><volume>43</volume><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.janxdis.2016.07.009</pub-id><pub-id pub-id-type="pmid">27497667</pub-id>
</element-citation></ref><ref id="B100-pharmacy-13-00021"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selinger</surname><given-names>C.P.</given-names></name>
<name><surname>Carbery</surname><given-names>I.</given-names></name>
<name><surname>Warren</surname><given-names>V.</given-names></name>
<name><surname>Rehman</surname><given-names>A.F.</given-names></name>
<name><surname>Williams</surname><given-names>C.J.</given-names></name>
<name><surname>Mumtaz</surname><given-names>S.</given-names></name>
<name><surname>Bholah</surname><given-names>H.</given-names></name>
<name><surname>Sood</surname><given-names>R.</given-names></name>
<name><surname>Gracie</surname><given-names>D.J.</given-names></name>
<name><surname>Hamlin</surname><given-names>P.J.</given-names></name>
<etal/>
</person-group><article-title>The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease</article-title><source>Aliment. Pharmacol. Ther.</source><year>2017</year><volume>45</volume><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/apt.13831</pub-id><pub-id pub-id-type="pmid">27778366</pub-id>
</element-citation></ref><ref id="B101-pharmacy-13-00021"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Greenley</surname><given-names>R.N.</given-names></name>
<name><surname>Kunz</surname><given-names>J.H.</given-names></name>
<name><surname>Walter</surname><given-names>J.</given-names></name>
<name><surname>Hommel</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Practical strategies for enhancing adherence to treatment regimen in inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2013</year><volume>19</volume><fpage>1534</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1097/MIB.0b013e3182813482</pub-id><pub-id pub-id-type="pmid">23635715</pub-id>
</element-citation></ref><ref id="B102-pharmacy-13-00021"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zurovac</surname><given-names>D.</given-names></name>
<name><surname>Larson</surname><given-names>B.A.</given-names></name>
<name><surname>Sudoi</surname><given-names>R.K.</given-names></name>
<name><surname>Snow</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Costs and Cost-Effectiveness of a Mobile Phone Text-Message Reminder Programmes to Improve Health Workers&#x02019; Adherence to Malaria Guidelines in Kenya</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e52045</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0052045</pub-id><pub-id pub-id-type="pmid">23272206</pub-id>
</element-citation></ref><ref id="B103-pharmacy-13-00021"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Conn</surname><given-names>V.S.</given-names></name>
<name><surname>Ruppar</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Medication adherence outcomes of 771 intervention trials: Systematic review and meta-analysis</article-title><source>Prev. Med.</source><year>2017</year><volume>99</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2017.03.008</pub-id><pub-id pub-id-type="pmid">28315760</pub-id>
</element-citation></ref><ref id="B104-pharmacy-13-00021"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wiecek</surname><given-names>E.</given-names></name>
<name><surname>Tonin</surname><given-names>F.S.</given-names></name>
<name><surname>Torres-Robles</surname><given-names>A.</given-names></name>
<name><surname>Benrimoj</surname><given-names>S.I.</given-names></name>
<name><surname>Fernandez-Llimos</surname><given-names>F.</given-names></name>
<name><surname>Garcia-Cardenas</surname><given-names>V.</given-names></name>
</person-group><article-title>Temporal effectiveness of interventions to improve medication adherence: A network meta-analysis</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0213432</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0213432</pub-id><pub-id pub-id-type="pmid">30861014</pub-id>
</element-citation></ref><ref id="B105-pharmacy-13-00021"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pai</surname><given-names>A.L.</given-names></name>
<name><surname>Ostendorf</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Treatment adherence in adolescents and young adults affected by chronic illness during the health care transition from pediatric to adult health care: A literature review</article-title><source>Child. Health Care</source><year>2011</year><volume>40</volume><fpage>16</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1080/02739615.2011.537934</pub-id></element-citation></ref><ref id="B106-pharmacy-13-00021"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agh</surname><given-names>T.</given-names></name>
</person-group><article-title>Comparative Analysis of Medication Possession Ratio Measures for Adherence to Single-Medication</article-title><source>Value Health</source><year>2016</year><volume>19</volume><fpage>A481</fpage><comment>Available online: <ext-link xlink:href="https://www.academia.edu/124279741/Comparative_Analysis_Of_Medication_Possession_Ratio_Measures_For_Adherence_To_Single_Medication" ext-link-type="uri">https://www.academia.edu/124279741/Comparative_Analysis_Of_Medication_Possession_Ratio_Measures_For_Adherence_To_Single_Medication</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.1016/j.jval.2016.09.777</pub-id></element-citation></ref><ref id="B107-pharmacy-13-00021"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moshkovska</surname><given-names>T.</given-names></name>
<name><surname>Stone</surname><given-names>M.</given-names></name>
<name><surname>Baker</surname><given-names>R.</given-names></name>
<name><surname>Mayberry</surname><given-names>J.</given-names></name>
</person-group><article-title>Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis</article-title><source>Inflamm. Bowel Dis.</source><year>2008</year><volume>14</volume><fpage>763</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1002/ibd.20404</pub-id><pub-id pub-id-type="pmid">18286644</pub-id>
</element-citation></ref><ref id="B108-pharmacy-13-00021"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kruis</surname><given-names>W.</given-names></name>
<name><surname>Kiudelis</surname><given-names>G.</given-names></name>
<name><surname>R&#x000e1;cz</surname><given-names>I.</given-names></name>
<name><surname>Gorelov</surname><given-names>I.A.</given-names></name>
<name><surname>Pokrotnieks</surname><given-names>J.</given-names></name>
<name><surname>Horynski</surname><given-names>M.</given-names></name>
<name><surname>Batovsky</surname><given-names>M.</given-names></name>
<name><surname>Kykal</surname><given-names>J.</given-names></name>
<name><surname>Boehm</surname><given-names>S.</given-names></name>
<name><surname>Greinwald</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Once daily versus three times daily mesalazine granules in active ulcerative colitis: A double-blind, double dummy, randomised, noninferiority trial</article-title><source>Gut</source><year>2009</year><volume>58</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1136/gut.2008.154302</pub-id><pub-id pub-id-type="pmid">18832520</pub-id>
</element-citation></ref><ref id="B109-pharmacy-13-00021"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Long</surname><given-names>M.D.</given-names></name>
<name><surname>Kappelman</surname><given-names>M.D.</given-names></name>
<name><surname>Martin</surname><given-names>C.F.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Anton</surname><given-names>K.</given-names></name>
<name><surname>Sandler</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Risk factors for depression in the elderly inflammatory bowel disease population</article-title><source>J. Crohns Colitis</source><year>2014</year><volume>8</volume><fpage>113</fpage><lpage>119</lpage><comment>Available online: <ext-link xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4589203/" ext-link-type="uri">https://pmc.ncbi.nlm.nih.gov/articles/PMC4589203/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.1016/j.crohns.2013.07.002</pub-id><pub-id pub-id-type="pmid">23932782</pub-id>
</element-citation></ref><ref id="B110-pharmacy-13-00021"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCombie</surname><given-names>A.M.</given-names></name>
<name><surname>Mulder</surname><given-names>R.T.</given-names></name>
<name><surname>Gearry</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Psychotherapy for inflammatory bowel disease: A review and update</article-title><source>J. Crohns Colitis</source><year>2013</year><volume>7</volume><fpage>935</fpage><lpage>949</lpage><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/23466412/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/23466412/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.1016/j.crohns.2013.02.004</pub-id><pub-id pub-id-type="pmid">23466412</pub-id>
</element-citation></ref><ref id="B111-pharmacy-13-00021"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodhand</surname><given-names>J.R.</given-names></name>
<name><surname>Wahed</surname><given-names>M.</given-names></name>
<name><surname>Rampton</surname><given-names>D.S.</given-names></name>
</person-group><article-title>Management of stress in inflammatory bowel disease: A therapeutic option?</article-title><source>Expert Rev. Gastroenterol. Hepatol.</source><year>2009</year><volume>3</volume><fpage>661</fpage><lpage>679</lpage><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/19929586/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/19929586/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.1586/egh.09.55</pub-id><pub-id pub-id-type="pmid">19929586</pub-id>
</element-citation></ref><ref id="B112-pharmacy-13-00021"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asamoah-Boaheng</surname><given-names>M.</given-names></name>
<name><surname>Osei Bonsu</surname><given-names>K.</given-names></name>
<name><surname>Farrell</surname><given-names>J.</given-names></name>
<name><surname>Oyet</surname><given-names>A.</given-names></name>
<name><surname>Midodzi</surname><given-names>W.K.</given-names></name>
</person-group><article-title>Measuring Medication Adherence in a Population-Based Asthma Administrative Pharmacy Database: A Systematic Review and Meta-Analysis</article-title><source>Clin. Epidemiol.</source><year>2021</year><volume>13</volume><fpage>981</fpage><lpage>1010</lpage><!--<pub-id pub-id-type="pmcid">PMC8547830</pub-id>--><pub-id pub-id-type="doi">10.2147/CLEP.S333534</pub-id><pub-id pub-id-type="pmid">34712061</pub-id>
</element-citation></ref><ref id="B113-pharmacy-13-00021"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anghel</surname><given-names>L.A.</given-names></name>
<name><surname>Farcas</surname><given-names>A.M.</given-names></name>
<name><surname>Oprean</surname><given-names>R.N.</given-names></name>
</person-group><article-title>An overview of the common methods used to measure treatment adherence</article-title><source>Med. Pharm. Rep.</source><year>2019</year><volume>92</volume><fpage>117</fpage><lpage>122</lpage><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/31086837/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/31086837/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.15386/mpr-1201</pub-id><pub-id pub-id-type="pmid">31086837</pub-id>
</element-citation></ref><ref id="B114-pharmacy-13-00021"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Julsgaard</surname><given-names>M.</given-names></name>
<name><surname>Norgaard</surname><given-names>M.</given-names></name>
<name><surname>Hvas</surname><given-names>C.L.</given-names></name>
<name><surname>Hasseriis</surname><given-names>S.</given-names></name>
<name><surname>Christensen</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during postpartum period in women with Crohn&#x02019;s disease</article-title><source>Scand. J. Gastroenterol.</source><year>2014</year><volume>49</volume><fpage>958</fpage><lpage>966</lpage><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/24897523/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/24897523/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.3109/00365521.2014.920913</pub-id><pub-id pub-id-type="pmid">24897523</pub-id>
</element-citation></ref><ref id="B115-pharmacy-13-00021"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kane</surname><given-names>S.</given-names></name>
<name><surname>Lemieux</surname><given-names>N.</given-names></name>
</person-group><article-title>The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease</article-title><source>Am. J. Gastroenterol.</source><year>2005</year><volume>100</volume><fpage>102</fpage><lpage>105</lpage><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/15654788/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/15654788/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-20">(accessed on 20 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.40785.x</pub-id><pub-id pub-id-type="pmid">15654788</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmacy-13-00021-f001"><label>Figure 1</label><caption><p>Rates of non-adherence. (Note: The range of non-adherence (4.3&#x02013;88.9%) reflects variations in study populations, adherence definitions and measurement methodologies).</p></caption><graphic xlink:href="pharmacy-13-00021-g001" position="float"/></fig><table-wrap position="float" id="pharmacy-13-00021-t001"><object-id pub-id-type="pii">pharmacy-13-00021-t001_Table 1</object-id><label>Table 1</label><caption><p>Quantitative measures of non-adherence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Measures of Non-Adherence </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Version </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Studies</th></tr></thead><tbody><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Self-report: medication adherence report scale (MARS)</td><td align="left" valign="middle" rowspan="1" colspan="1">Not specified </td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4 </td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B45-pharmacy-13-00021" ref-type="bibr">45</xref>,<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5 </td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B48-pharmacy-13-00021" ref-type="bibr">48</xref>,<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>,<xref rid="B60-pharmacy-13-00021" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10-item scale </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>]</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Self-report: Morisky medication adherence scale (MMAS)</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-specific (4 items) </td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B49-pharmacy-13-00021" ref-type="bibr">49</xref>,<xref rid="B50-pharmacy-13-00021" ref-type="bibr">50</xref>,<xref rid="B61-pharmacy-13-00021" ref-type="bibr">61</xref>,<xref rid="B62-pharmacy-13-00021" ref-type="bibr">62</xref>,<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>,<xref rid="B64-pharmacy-13-00021" ref-type="bibr">64</xref>,<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Non-specific (6 item) </td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="B21-pharmacy-13-00021" ref-type="bibr">21</xref>]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Non-specific (8 item) </td><td align="left" valign="middle" rowspan="1" colspan="1">[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B39-pharmacy-13-00021" ref-type="bibr">39</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>,<xref rid="B68-pharmacy-13-00021" ref-type="bibr">68</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>] </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For IBD patients (8 item)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B46-pharmacy-13-00021" ref-type="bibr">46</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-report: Medication adherence (non-validated) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(23 items) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-report: <break/>Visual analogue <break/>scale (VAS) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-pharmacy-13-00021" ref-type="bibr">24</xref>,<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-report: QUOTE-IBD questionnaire</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-standardised multiple-choice test with <break/>open-ended questions</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-report: study&#x02019;s <break/>own questionnaire</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E.g. individual questions, <break/>Likert scale, ordinal scale</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B22-pharmacy-13-00021" ref-type="bibr">22</xref>,<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B43-pharmacy-13-00021" ref-type="bibr">43</xref>,<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B51-pharmacy-13-00021" ref-type="bibr">51</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>,<xref rid="B76-pharmacy-13-00021" ref-type="bibr">76</xref>,<xref rid="B77-pharmacy-13-00021" ref-type="bibr">77</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>,<xref rid="B79-pharmacy-13-00021" ref-type="bibr">79</xref>,<xref rid="B80-pharmacy-13-00021" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-report: verbal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amount/dose of treatment or incidents taken or missed within a specific time period </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>,<xref rid="B81-pharmacy-13-00021" ref-type="bibr">81</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>,<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medical records</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reviewed by researchers </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>,<xref rid="B77-pharmacy-13-00021" ref-type="bibr">77</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pill count</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(Short-term measure of adherence) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medication possession ratio (MPR) *</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% of prescribed <break/>medication dispensed to a <break/>patient during a specific period </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>,<xref rid="B23-pharmacy-13-00021" ref-type="bibr">23</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>,<xref rid="B84-pharmacy-13-00021" ref-type="bibr">84</xref>,<xref rid="B85-pharmacy-13-00021" ref-type="bibr">85</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>,<xref rid="B87-pharmacy-13-00021" ref-type="bibr">87</xref>,<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>,<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proportion of days covered (PDC) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Number of any oral 5-ASA drug <break/>on hand during a 1-year <break/>period (different to MPR). </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood tests (thiopurine levels)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>] </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B60-pharmacy-13-00021" ref-type="bibr">60</xref>,<xref rid="B91-pharmacy-13-00021" ref-type="bibr">91</xref>,<xref rid="B92-pharmacy-13-00021" ref-type="bibr">92</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Key: * The medication possession ratio (MPR) is the proportion of medication supply dispensed, presuming that the previous prescription was not filled within the first and last dispensed date [<xref rid="B94-pharmacy-13-00021" ref-type="bibr">94</xref>,<xref rid="B95-pharmacy-13-00021" ref-type="bibr">95</xref>]. Adherence using MPR is usually defined as &#x02265;80%, and non-adherence &#x0003c;80%.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmacy-13-00021-t002"><object-id pub-id-type="pii">pharmacy-13-00021-t002_Table 2</object-id><label>Table 2</label><caption><p>Factors associated with non-adherence/low adherence in studies using multivariate analysis (mva), multiple logistic regression or factor analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Categories</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Individual Factors Associated with Non-Adherence/Low Adherence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relationship</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Studies</th></tr></thead><tbody><tr><td rowspan="15" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Age </td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Younger age (15&#x02013;29 years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>,<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>,<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>]<break/>[<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>] (specific age range not stated)<break/>[<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>] (males, &#x0003c;40 years)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Early middle age<break/>(30&#x02013;45 years above)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]<break/>[<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>] (significant for all patients &#x0003c;40 years (<italic toggle="yes">p</italic> = 0.034), yet in terms of sex only females significantly associated &#x0003c;40 years (<italic toggle="yes">p</italic> = 0.002))</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>]<break/>[<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>] (not significant in males &#x0003c;40 years)<break/>[<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>] (specific age range not stated)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Late middle age<break/>(46&#x02013;60 years above)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>]<break/>[<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>] (specific age range not stated)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Older age<break/>(61 years+)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>] (older patients had less recall, rating themselves non-adherent)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>] (specific age range not stated)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Increased feeling of being<break/>between adolescence and adulthood</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Age at<break/>Diagnosis</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Younger age at diagnosis<break/>(Up to 29 years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>,<xref rid="B84-pharmacy-13-00021" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sex</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>,<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B62-pharmacy-13-00021" ref-type="bibr">62</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]<break/>[<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>] (in UC)<break/>[<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>] (in whole population and CD, but not UC)<break/>[<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>] (in terms of sex, only females &#x0003c;40 years old)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Race</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">African&#x02013;Caribbean descent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>]</td></tr><tr><td rowspan="21" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Diagnosis</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Crohn&#x02019;s disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B60-pharmacy-13-00021" ref-type="bibr">60</xref>,<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ulcerative colitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IBD unclassified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Distal involvement (ulcerative colitis)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Perianal/perineal disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Length of time since diagnosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>] (increased time since diagnosis)<break/>[<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>] (&#x0201c;short&#x0201d; diagnosis duration, &#x02264;5 years)<break/>[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>] (&#x0201c;long&#x0201d; diagnosis duration, 6&#x02013;15 years)<break/>[<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>] (&#x0201c;long&#x0201d; diagnosis duration, 6&#x02013;15 years with whole population and UC, but not CD)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>] (&#x0201c;long&#x0201d; diagnosis duration, 6&#x02013;15 years)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>] (&#x0201c;short&#x0201d; diagnosis duration, &#x02264;5 years)<break/>[<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>,<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>,<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>] (&#x0201c;long&#x0201d; diagnosis duration, 6&#x02013;15 years)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Disease activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>] (active disease/not in remission);<break/>[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (lower relapse probability)<break/>[<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>] (inactive disease/in remission)<break/>[<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>] (absence of physical bleeding)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>] (having at least one relapse in past 12 months)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>] (active disease/not in remission)<break/>[<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (inactive disease/in remission)<break/>[<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>] (being in pain/discomfort)</td></tr><tr><td rowspan="39" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Treatment</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Aminosalicylates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Thiopurines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>] (no concomitant use of thiopurines)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biologics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>] (intravenous/self-administering biologics)<break/>[<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>] (greatest non-adherence in combination therapy of biologic and immunomodulator, then infliximab, then adalimumab)<break/>[<xref rid="B87-pharmacy-13-00021" ref-type="bibr">87</xref>] (intravenous/self-administering biologics only within 1st 12 months of treatment)<break/>[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>] (intravenous/self-administering biologics; greatest non-adherence in adalimumab (43%), then infliximab (8%))<break/>[<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>] (self-administering biologics only)<break/>[<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>] (not using biologics)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>] (self-administering biologics only)<break/>[<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>] (intravenous and self-administering biologics)<break/>[<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>] (not using biologics)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Steroids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>] (prescribed steroid script)<break/>[<xref rid="B2-pharmacy-13-00021" ref-type="bibr">2</xref>] (not using steroids)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>] (prescribed steroid script)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Antibiotics or topical steroids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>] (either)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Immunosuppressants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>] (not using immunosuppressants)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biologics/immunosuppressants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>] (no use of biologics/immunosuppressants within 12 months post-index date)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B79-pharmacy-13-00021" ref-type="bibr">79</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>] (frequent/multiple-daily dose, e.g., &#x02265;3 times daily)<break/>[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>] (regimen of 40 mg adalimumab every other week as opposed to 40 mg every week)<break/>[<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>] (starting multiple daily dosing of either: balsalazide, mesalamine-delayed release (Asacol) or sulfasalazine)<break/>[<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>] (less frequent/fewer daily medications; &#x0003c;8 daily tablets)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>] (frequent/multiple-daily dose; regimen of 80 mg every other week, as opposed to 40 mg every other week)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>] (less frequent/fewer daily medications&#x02014;monotherapy)<break/>[<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>] (starting once-daily regime: &#x0201c;Multi-Matrix System&#x0201d; mesalamine/Lialda)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ongoing/lengthy treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-pharmacy-13-00021" ref-type="bibr">62</xref>,<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pill-burden (e.g., problem with<break/>dosing time regimen, high<break/>pill frequency or pill size)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>] (time of dosing or pill size)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Route</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>] (subcutaneous rather than oral)<break/>[<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>] (not using rectal 5-ASA)<break/>[<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>] (topical medication)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>] (topical medication)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Presence of adverse/side effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Induction treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>] (no history of switching from induction medication)<break/>[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>] (anti-TNF induction)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Healthcare</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Care perspectives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>,<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>] (negative relations/poor communication with HCP)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>] (perception of easy contact with gastroenterologist)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>] (negative relations/poor communication with HCP)<break/>[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B52-pharmacy-13-00021" ref-type="bibr">52</xref>] (lack of trust in gastroenterologist)<break/>[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>] (poor patient satisfaction)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Care experienced</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (lack of treatment information from clinical team)<break/>[<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>,<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>] (no specialist/tailored care/follow-up by GP)<break/>[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (lack of physician reinforcement regarding importance of treatment adherence)<break/>[<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>] (&#x02264;1 month between outpatient clinic appointment)<break/>[<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>] (frequent emergency care)<break/>[<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>,<xref rid="B86-pharmacy-13-00021" ref-type="bibr">86</xref>] (frequent inpatient hospitalisation)<break/>[<xref rid="B83-pharmacy-13-00021" ref-type="bibr">83</xref>] (no history of IBD related surgery, CD patients)<break/>[<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>] (fewer all-cause healthcare appointments)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>] (lack of/poor treatment information from clinical team)<break/>[<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>] (lack of involvement in prescribing)<break/>[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>] (frequent inpatient hospitalisation)<break/>[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>] (no history of IBD related surgery)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Medication-taking behaviour close to<break/>timing of clinic visits</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">General<break/>Health</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Receiving treatment for other<break/>chronic condition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (use of treatment for other chronic condition/s)<break/>[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>] (use of treatment for other chronic condition/s when prescribed 5-ASA for IBD);<break/>[<xref rid="B84-pharmacy-13-00021" ref-type="bibr">84</xref>] (not prescribed other chronic treatment)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-pharmacy-13-00021" ref-type="bibr">55</xref>] (use of treatment for other chronic condition/s)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Having a disability certificate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Comorbidities</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Habits</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Smoking</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B3-pharmacy-13-00021" ref-type="bibr">3</xref>,<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>] (current smoker)<break/>[<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>] (male only current smoker)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>] (current smoker)<break/>[<xref rid="B54-pharmacy-13-00021" ref-type="bibr">54</xref>] (non-smoker)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>,<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>,<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>] (current smoker)<break/>[<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>] (current smokers with CD)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Alcohol consumption</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>] (whole population)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>]<break/>[<xref rid="B53-pharmacy-13-00021" ref-type="bibr">53</xref>] (females only)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prescribed narcotic use<break/>(at time of biologic initiation)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>]</td></tr><tr><td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Diet</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Frequently eating alone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Frequently missing a meal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-pharmacy-13-00021" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Not storing treatment near to where<break/>meals are eaten</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Use of nutritional supplements</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Finance</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Healthcare/pharmacy prescription costs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B7-pharmacy-13-00021" ref-type="bibr">7</xref>] (lower UC pharmacy prescription patient costs and/or overall higher healthcare costs for patients)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (higher healthcare cost perception for patient appointments/treatment)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Income/socioeconomic status</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>] (lower socioeconomic status)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>] (higher income)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>] (higher socioeconomic status)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Having public/non-commercial insurance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>,<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>,<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Living<break/>Location</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Country of residence (UK instead of Australia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Living in north-east, south or west America</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Living in mid-west America</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-pharmacy-13-00021" ref-type="bibr">90</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Poor residential area/Poor QoL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (reduced/poor quality of life)<break/>[<xref rid="B26-pharmacy-13-00021" ref-type="bibr">26</xref>,<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>] (living in a poor residential area)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Employment</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Employment type</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>] (employed)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>] (self-employed)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>] (permanent employment)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Professional<break/>constraints</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>] (demanding jobs)<break/>[<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>] (work rhythms/constraints relating to treatment)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Education</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Educational level</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>] (lower educational level)<break/>[<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>] (higher educational level)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>] (higher educational level)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Combined higher educational, occupational and<break/>socioeconomic status</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Social support<break/>+<break/>Relationships</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Being single</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-pharmacy-13-00021" ref-type="bibr">93</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Poor/low social support</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>] (received, emotional, tangible)<break/>[<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>] (informational)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-pharmacy-13-00021" ref-type="bibr">57</xref>] (received, emotional, tangible)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Having friends</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>] (dealing with friends when experiencing CD)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="18" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Psychology</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Treatment beliefs/perceptions/concerns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (belief treatment is ineffective)<break/>[<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>] (belief treatment is ineffective in CD)<break/>[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>,<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>] (belief there is no/little need for treatment/scepticism)<break/>[<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>] (negative beliefs about medication and poor patient satisfaction)<break/>[<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>] (lower perceived competence with treatment regime)<break/>[<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>] (lower perceived control over disease)<break/>[<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>] (negative beliefs about taking aminosalicylates: susceptibility, severity, benefits, barriers and cues to action)<break/>[<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>,<xref rid="B69-pharmacy-13-00021" ref-type="bibr">69</xref>] (side effect concerns)<break/>[<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>] (adverse effect concerns)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>] (belief there is a need for treatment)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>,<xref rid="B78-pharmacy-13-00021" ref-type="bibr">78</xref>] (belief treatment is ineffective)<break/>[<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>] (belief for no/little need for treatment/scepticism)<break/>[<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>] (lower perceived competence with treatment regime)<break/>[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>] (lower perceived control over disease)<break/>[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (side effects and efficacy concerns)<break/>[<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>] (potential for harm of medication in general concerns)<break/>[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>,<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>] (potential adverse effects concerns)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Illness beliefs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>] (shorter timeline perception/perceptions of IBD as an acute episodic disease)<break/>[<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>] (shorter perceived illness duration in CD; &#x0201c;perceptions that CD will end too soon&#x0201d;)<break/>[<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>] (shorter perceived illness duration in UC)<break/>[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>] (illness identity)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>] (illness consequences)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Depressive symptoms/antidepressant use/<break/>psychiatric history</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-pharmacy-13-00021" ref-type="bibr">25</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>,<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>,<xref rid="B92-pharmacy-13-00021" ref-type="bibr">92</xref>] (depressive symptoms/antidepressant use)<break/>[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>] (patient-reported diagnosis and/or depression score from HADS)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-pharmacy-13-00021" ref-type="bibr">89</xref>] (history of psychiatric disease in CD)<break/>[<xref rid="B88-pharmacy-13-00021" ref-type="bibr">88</xref>] (comorbid psychiatric disease with IBD, e.g., depression and/or anxiety)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mood and attitude</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>] (low influence of disease on mood)<break/>[<xref rid="B56-pharmacy-13-00021" ref-type="bibr">56</xref>] (indifferent attitude/less bothered regarding treatment benefit)<break/>[<xref rid="B6-pharmacy-13-00021" ref-type="bibr">6</xref>] (stronger emotional response/negative emotions resulting from IBD)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>] (low influence of disease on mood)<break/>[<xref rid="B72-pharmacy-13-00021" ref-type="bibr">72</xref>] (feeling stressed)<break/>[<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>] (lower sense of coherence)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Anxiety</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>,<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Negative religious coping<break/>(questions, doubt and strain around sacred matters with the divine, oneself and others)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-pharmacy-13-00021" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="21" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Accessibility, Organisation and Planning</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Forgetting/disorganisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-pharmacy-13-00021" ref-type="bibr">40</xref>] (forgetfulness)<break/>[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B71-pharmacy-13-00021" ref-type="bibr">71</xref>] (missing scheduled appointments)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>] (forgetfulness/carelessness)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">At weekends</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-pharmacy-13-00021" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Not keeping medications accessible<break/>when due</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-pharmacy-13-00021" ref-type="bibr">67</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Not being as careful when taking medications</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lower priority for medications</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-pharmacy-13-00021" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Fewer cues to action (e.g., reminders<break/>to take medication)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-pharmacy-13-00021" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Not using adherence tools<break/>(e.g., dosette boxes, alarms)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-pharmacy-13-00021" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="15" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Knowledge and Understanding</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Poor/inadequate disease/<break/>treatment knowledge</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-pharmacy-13-00021" ref-type="bibr">11</xref>] (poor understanding of IBD as a disease)<break/>[<xref rid="B59-pharmacy-13-00021" ref-type="bibr">59</xref>] (poor understanding of specifically CD)<break/>[<xref rid="B74-pharmacy-13-00021" ref-type="bibr">74</xref>] (poor understanding of specifically UC)<break/>[<xref rid="B58-pharmacy-13-00021" ref-type="bibr">58</xref>,<xref rid="B65-pharmacy-13-00021" ref-type="bibr">65</xref>] (poor treatment knowledge)<break/>[<xref rid="B66-pharmacy-13-00021" ref-type="bibr">66</xref>] (having inadequate information about treatment)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Poor recall of medical information</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Internet use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-pharmacy-13-00021" ref-type="bibr">41</xref>] (not keen on using internet)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Being an information seeker/<break/>having high curiosity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>] (being an information seeker)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>] (having high curiosity)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Patient organisation membership</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-pharmacy-13-00021" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmacy-13-00021" ref-type="bibr">8</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Alternative<break/>treatments</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Complementary and alternative medicine (CAM) use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-pharmacy-13-00021" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No studies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-pharmacy-13-00021" ref-type="bibr">75</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: GP: general practitioner (family doctor); HADS: Hospital Anxiety and Depression Scale; HCP: Healthcare professionals; QoL: quality of life; UK: United Kingdom. Key: + = positive association with non-adherence; &#x02212; = negative association with non-adherence; NS: non-significant association with non-adherence on MVA/factor analysis; blank cells = data not reported; [<xref rid="B70-pharmacy-13-00021" ref-type="bibr">70</xref>]: age younger than 40 years old.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmacy-13-00021-t003"><object-id pub-id-type="pii">pharmacy-13-00021-t003_Table 3</object-id><label>Table 3</label><caption><p>Design of qualitative studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Qualitative or Mixed Methods</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Data Collection Methods</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>],</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Focus group</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quantitative and qualitative</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Questionnaire with free text options </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quantitative and qualitative</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interviews and focus groups</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interviews and focus groups</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative section within largely quantitative paper</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Data from IBD Spanish database: electronic medical records reviewed </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Social media posts: online with descriptive content analysis conducted</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative section within largely quantitative paper</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Online questionnaire with free text options </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmacy-13-00021" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative section within largely quantitative paper</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recorded consultation with nurse (questionnaire completion pre and post) and 3-week follow-up telephone interview</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative section within largely quantitative paper</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-administered questionnaires with free text responses</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-pharmacy-13-00021" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative section within largely quantitative paper</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-administered questionnaire with free text responses </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative section within largely quantitative paper</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interviews with questionnaire followed by free text responses</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B9-pharmacy-13-00021" ref-type="bibr">9</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative section within largely quantitative paper</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two open-ended questions within a questionnaire. Questionnaire completion via email/during clinic visits and medical records reviewed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-pharmacy-13-00021" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qualitative section within largely quantitative paper</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple choice questionnaire with some open-ended questions</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmacy-13-00021-t004"><object-id pub-id-type="pii">pharmacy-13-00021-t004_Table 4</object-id><label>Table 4</label><caption><p>Qualitative data/free-text analysis/specific reasons reported for non-adherence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Theme</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reasons for Non-Adherence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Studies</th></tr></thead><tbody><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Disease/condition</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feeling better/being in remission</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feeling unwell/hospitalisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No effect of medication/worsening of disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td></tr><tr><td rowspan="7" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Treatment</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Side effects/adverse effects </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complicated/difficult administration mode (pill size/discomfort/pain) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Too many drugs/frequent drug dosing/regimen </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pill fatigue</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Life-long treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment response time</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>] </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug safety</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Healthcare</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Distrust/poor confidence in healthcare provider</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lack of convincing benefit based on doctor&#x02019;s explanation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Background and general health</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Having an infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eating</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fasting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Finance</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment cost</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Work/occupation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not taking treatment to work</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Lifestyle</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Busy life</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change of routine (weekend/vacation)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Being in public/social stigma </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Travel/away from home</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>] </td></tr><tr><td rowspan="7" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Beliefs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Perception of treatment necessity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment fear, anxiety and uncertainty </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stress/pressure</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scepticism about treatment efficacy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>] </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment being disease reminder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease non-acceptance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intentional non-adherence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-13-00021" ref-type="bibr">34</xref>] </td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Forgetting and organisation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Forgetting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Timing/carelessness/disorganised</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmacy-13-00021" ref-type="bibr">30</xref>,<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Accessibility</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment accessibility (including through GP/pharmacies/hospitals)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Running out of treatment (whilst at home)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>,<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Refill inconvenience</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Knowledge and understanding</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lack of understanding regarding treatment regime</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmacy-13-00021" ref-type="bibr">32</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lack of understanding regarding treatment benefits</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Alternatives&#x0201d; to prescribed treatment</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Using &#x0201c;healthier&#x0201d; alternatives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Pregnancy and pregnancy planning</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infertility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>] *</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pregnancy/avoiding perceived harm for current baby</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-pharmacy-13-00021" ref-type="bibr">33</xref>,<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avoiding all treatment for their next pregnancy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Independent research</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information gathered from online sources/online communities </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-disclosed</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Personal reasons</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: GP: general practitioner/family Doctor. Key: * [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]: Infertility concerns were reported by both male and female participants with regards to taking IBD medications. Note: Ref. [<xref rid="B35-pharmacy-13-00021" ref-type="bibr">35</xref>] collected and analysed qualitative variables, recording these according to the international classification of diseases (ICD), including chronic and psychiatric pathologies, expressed as frequencies (%). However, no demographic, phenotypic factors of the disease or therapeutic regimes were predictors of thiopurine non-adherence. Ref. [<xref rid="B64-pharmacy-13-00021" ref-type="bibr">64</xref>] collected qualitative data regarding information-seeking sources and themes, but not the reasons for non-adherence, and thus not data relevant for the above table.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmacy-13-00021-t005"><object-id pub-id-type="pii">pharmacy-13-00021-t005_Table 5</object-id><label>Table 5</label><caption><p>Themes, sub-themes and qualitative quotations for non-adherence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Theme</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sub-Themes for Non-Adherence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Qualitative Quotations for Non-Adherence</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Treatment</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Side effects/adverse effects </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Because of fears of side effects.&#x0201d; [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;I&#x02019;ve had some that make me jerk like a puppet&#x02026;Side effects that you didn&#x02019;t know, didn&#x02019;t need and don&#x02019;t want, and it&#x02019;s so bad for you; you just stop because it&#x02019;s&#x02026; too much.&#x0201d; [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug safety</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Humira is so new that most Dr&#x02019;s [doctors] don&#x02019;t have a clue when we ask about complications.&#x0201d; [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complicated/difficult administration mode (pill size/discomfort/pain) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Those ones in the leg, would just, aaaarghh (shudders), and I know it&#x02019;s coming and it was really hard&#x02026; I felt sore&#x02026; taking it all the time.&#x0201d; [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pill fatigue</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;That&#x02019;s really the biggest thing&#x02026; I just have to take it in the morning, and then every once in a while, I&#x02019;m just sick of taking it.&#x0201d; [<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Too many drugs/frequent drug dosing/regimen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;I take four of one kind twice a day; it would be awesome if that could be reduced down to one pill&#x02026; &#x02018;cos by the time you&#x02019;ve had three devils&#x02026; you choke on the pill&#x02026; the big horse ones which have a nice coating, but they still get stuck down your throat.&#x0201d; [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>] </td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Finance</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Treatment cost</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Because medication is expensive.&#x0201d; [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;If you get a repeat prescription and you had to go to the GP and they said so that&#x02019;s gonna be $60 or a $100, I would go: I don&#x02019;t have $100 or I have $100 but it makes a kind a financial thing.&#x0201d; [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lifestyle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Travel/away from home</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Boxes of medications that&#x02019;s just especially if you&#x02019;re travelling overseas&#x02026; makes for a very bulky parcel, and then there&#x02019;s sometimes you get to your hotel room and you don&#x02019;t have a fridge&#x02026; it&#x02019;s pretty much a nightmare, pretty challenging.&#x0201d; [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beliefs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease non-acceptance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;So you develop an intense dislike that you have to take them because it makes you angry.&#x0201d; [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Forgetting and Organisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Forgetting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Because I forget.&#x0201d; [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Timing/carelessness/disorganised</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;I have a terrible memory so may have forgotten and just not realised&#x02026; I take it a couple hours later when I remember.&#x0201d; [<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Accessibility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment accessibility (including through GP/pharmacies/hospitals)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Because medication is not available in pharmacies.&#x0201d; [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Running out of treatment (whilst at home)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Because I run out of medications before I get a new prescription.&#x0201d; [<xref rid="B29-pharmacy-13-00021" ref-type="bibr">29</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Refill inconvenience</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;When you go to refill it and you&#x02019;ve passed the pharmacy hours or something. You just forgot or it wasn&#x02019;t convenient.&#x0201d; [<xref rid="B37-pharmacy-13-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;The week before when you pick up your last repeat, you&#x02019;ve got to then email. And sometimes they get it, sometimes they don&#x02019;t&#x02026; or it could be in their spam box.&#x0201d; [<xref rid="B36-pharmacy-13-00021" ref-type="bibr">36</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pregnancy and Pregnancy planning</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infertility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;My wife and I are most worried about having children soon or in the future but based on my research, you should not try while on the medication. Does anyone know any info on this? Please help!&#x0201d; [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pregnancy/avoiding perceived harm for current baby</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;My doctor now wants me to take Asacol HD and I&#x02019;m very hesitant to take any medication while pregnant for fear it may cause some kind of issue or birth defect with my baby.&#x0201d; [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Humira has not been fully studied in pregnant women&#x02026; I know of a horror story and pregnancy and humira.&#x0201d; [<xref rid="B38-pharmacy-13-00021" ref-type="bibr">38</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>